PMID,Multiple Answer,time_usage
18715920,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from culture supernatant or virus stock"" and ""cDNA encoding reverse transcriptase and IN was generated with Expand Reverse Transcriptase, followed by amplification of the IN region by nested PCR (1,456 bp)"". The paper also mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper reports that genetic sequencing was performed on clinical samples, specifically viral RNA extracted from culture supernatant or virus stock. The paper also mentions genotypic resistance testing and HIV sequencing, which suggests that the sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""the antiviral activity of different inhibitors was determined in a cell-based HIV-1 replication assay"" and ""the susceptibility of the HIV strains to the presence of high EVG concentrations were determined"". The paper also mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"".

Rationale: The paper reports that the antiviral activity of different inhibitors was determined in a cell-based HIV-1 replication assay, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to a public database or made available in a sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""cDNA encoding reverse transcriptase and IN was generated with Expand Reverse Transcriptase, followed by amplification of the IN region by nested PCR (1,456 bp)"".

Rationale: The paper reports that the IN region was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""PCR products were genotyped by automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing; Applied Biosystems, Foster City, CA)"".

Rationale: The paper reports that the sequencing method used was Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""viral RNA was extracted from culture supernatant or virus stock"".

Rationale: The paper reports that the samples sequenced were viral RNA extracted from culture supernatant or virus stock.

Answer: Viral RNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""the susceptibility of the HIV strains to the presence of high EVG concentrations were determined"" and ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper reports that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about the patients being in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""the susceptibility of the HIV strains to the presence of high EVG concentrations were determined"" and ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper reports that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the susceptibility of the HIV strains to the presence of high EVG concentrations were determined"" and ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper reports that the individuals in the study received INSTI drugs before sample sequencing.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the susceptibility of the HIV strains to the presence of high EVG concentrations were determined"" and ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper reports that the individuals in the study received EVG before sample sequencing.

Answer: EVG",91
19104010,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences. The paper also reports GenBank accession numbers for the sequences generated in this study, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all methods used to determine the susceptibility of HIV to different drugs. The paper also reports values such as IC50, EC50, and EC90, which are measures of drug susceptibility. Additionally, the paper mentions the use of named platforms like PhenoSense and Monogram, which are commonly used to determine drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to GenBank and other public databases, which indicates that the sequences are publicly available. Additionally, the paper reports accession numbers for the sequences, which can be used to retrieve the sequences from the databases.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper reports accession numbers for the sequences, but the specific accession numbers are not provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals.

Rationale: The paper does not provide a specific number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide information on the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper mentions pol genotyping/sequencing, which suggests that the pol gene was sequenced. However, the specific genes within the pol region are not specified.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments (ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant) or Beckman CEQ 2000 XL.

Rationale: The paper mentions ABI instruments, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions plasma samples, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimen.

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ARV drug treatment.

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention drug classes.

Rationale: The paper does not provide information on which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide information on which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported",105
21115794,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"" in the context of studying HIV integrase inhibitors.

Rationale: The paper reports on the development of a new HIV integrase inhibitor, S/GSK1349572, and its activity against HIV-1 in various cell-based assays. The paper mentions genotypic resistance testing and HIV sequencing, which suggests that the study involves analyzing HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports on the inhibitory potencies of S/GSK1349572 and other INIs against HIV-1 in various cell-based assays, including the MT-4 antiviral assay and the PHIV assay.

Rationale: The paper presents data on the inhibitory potencies of S/GSK1349572 and other INIs against HIV-1 in various cell-based assays, which suggests that the study involves in vitro drug susceptibility testing.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention depositing sequences in a public database or providing accession numbers.

Rationale: The paper does not provide any information on making the sequences publicly available, which suggests that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that the sequences are not publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing, which suggests that this information is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not provide any information on the country of origin of the samples, which suggests that this information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information on the year of sample collection, which suggests that this information is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples prior to sequencing, which suggests that this information is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the integrase gene.

Rationale: The paper reports on the development of a new HIV integrase inhibitor, S/GSK1349572, and its activity against HIV-1 in various cell-based assays. The paper mentions sequencing of the integrase gene, which suggests that this gene was the focus of the study.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing.

Rationale: The paper reports on the development of a new HIV integrase inhibitor, S/GSK1349572, and its activity against HIV-1 in various cell-based assays. The paper mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of viral RNA from plasma.

Rationale: The paper reports on the development of a new HIV integrase inhibitor, S/GSK1349572, and its activity against HIV-1 in various cell-based assays. The paper mentions sequencing of viral RNA from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information on virological failure on a treatment regimen, which suggests that this information is not reported.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial, which suggests that this information is not reported.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information on previous ARV drug use, which suggests that this information is not reported.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information on specific drug classes, which suggests that this information is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information on specific drugs, which suggests that this information is not reported.

Answer: Not reported",91
23749954,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" in the context of studying the preferential selection of the K65R resistance mutation in subtype C HIV-1.

Rationale: The paper reports on the results of genotypic resistance testing and HIV sequencing, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""cell culture drug selections"" and ""drug susceptibility assay"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the results of in vitro drug susceptibility assays, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in a public database or the availability of sequences for download.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that the accession numbers are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals, which suggests that the number is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries, which suggests that the countries are not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years, which suggests that the years are not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""molecular clones"" and ""cloning"" in the context of generating recombinant viruses.

Rationale: The paper reports on the use of cloning techniques to generate recombinant viruses, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""reverse transcriptase sequencing"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the sequencing of the pol gene, which includes the reverse transcriptase gene, which suggests that the reverse transcriptase gene was sequenced.

Answer: RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" in the context of generating sequences for the recombinant viruses.

Rationale: The paper reports on the use of Sanger sequencing, which suggests that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMCs"" in the context of generating recombinant viruses.

Rationale: The paper reports on the use of plasma and PBMCs as samples for sequencing, which suggests that both plasma and PBMCs were sequenced.

Answer: Plasma, PBMCs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the sequencing of viruses from individuals with virological failure, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about the patients being in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the sequencing of viruses from individuals who had previously received ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTIs"" and ""NNRTIs"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the use of NRTIs and NNRTIs, which suggests that individuals in the study received NRTIs and NNRTIs before sample sequencing.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir"", ""didanosine"", ""stavudine"", ""apricitabine"", and ""abacavir"" in the context of studying the resistance of HIV-1 to various antiretroviral drugs.

Rationale: The paper reports on the use of these specific drugs, which suggests that individuals in the study received these drugs before sample sequencing.

Answer: Tenofovir, didanosine, stavudine, apricitabine, abacavir",96
24227862,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper explicitly mentions phenotypic susceptibility testing and reports values such as IC50, EC50, and EC90, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and reports accession numbers, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly mentions that accession numbers were reported, but the actual accession numbers are not provided in the text.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals.

Rationale: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide information about the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide information about the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper explicitly mentions ""pol genotyping/sequencing"", which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" or ""ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant"" or ""Beckman CEQ 2000 XL"".

Rationale: The paper explicitly mentions Sanger sequencing, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper explicitly mentions plasma samples, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure (VF)"" or ""failing therapy or regimen"".

Rationale: The paper explicitly mentions virological failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions ART-experienced individuals, which indicates that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", ""NRTI"", ""INSTI"" and/or reports that patients received specific ARV drugs such as ""3TC"", ""FTC"", AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper explicitly mentions NRTI, PI, and INSTI drug classes, which indicates that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs such as ""3TC"", ""FTC"", AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper explicitly mentions specific ARV drugs, which indicates that these drugs were received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",111
25637519,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper explicitly mentions phenotypic susceptibility testing and reports IC50 values, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not mention that the sequences were made publicly available, which indicates that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which indicates that the accession numbers are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals, which indicates that the number is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not report the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin, which indicates that the country is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the years during which the sequenced samples were obtained.

Rationale: The paper does not mention the years, which indicates that the years are not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning, which indicates that cloning was not performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""reverse transcriptase (RT)"".

Rationale: The paper explicitly mentions pol genotyping/sequencing and reverse transcriptase (RT), which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"".

Rationale: The paper explicitly mentions Sanger sequencing and ABI instruments, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not mention the type of samples, which indicates that the type of samples is not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly mentions virologic failure and failing therapy, which indicates that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which indicates that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper explicitly mentions ART-experienced and treatment-experienced, which indicates that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", and ""PI"".

Rationale: The paper explicitly mentions NRTI, NNRTI, and PI, which indicates that these drug classes were received by individuals in the study.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""zidovudine"", ""abacavir"", ""lamivudine"", ""efavirenz"", ""nevirapine"", and ""ritonavir"".

Rationale: The paper explicitly mentions these drugs, which indicates that they were received by individuals in the study.

Answer: zidovudine, abacavir, lamivudine, efavirenz, nevirapine, ritonavir",86
26246578,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"" were performed on clinical samples from ""patients"" and ""participants"".

Rationale: The paper states that genetic sequencing was performed on clinical samples from patients and participants, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""drug susceptibility assay"", and ""IC50"" values, which indicates that in vitro drug susceptibility data was reported.

Rationale: The paper reports values such as IC50, which is a measure of drug susceptibility, and mentions phenotypic susceptibility assays, which indicates that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""site-directed mutagenesis"" and ""cloning"" of the integrase gene.

Rationale: The paper mentions cloning and site-directed mutagenesis, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""integrase"" and ""pol"" genes.

Rationale: The paper mentions the integrase and pol genes, which suggests that these genes were sequenced.

Answer: Integrase, Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI PRISM"" instruments.

Rationale: The paper mentions Sanger sequencing and ABI PRISM instruments, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" samples.

Rationale: The paper mentions plasma and PBMC samples, which suggests that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment-experienced"" individuals.

Rationale: The paper mentions virological failure and treatment-experienced individuals, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" individuals and ""ARV"" drugs.

Rationale: The paper mentions treatment-experienced individuals and ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI"" and ""NRTI"" drugs.

Rationale: The paper mentions INSTI and NRTI drugs, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""raltegravir"", ""elvitegravir"", and ""dolutegravir"" drugs.

Rationale: The paper mentions raltegravir, elvitegravir, and dolutegravir drugs, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Raltegravir, Elvitegravir, Dolutegravir",79
26311878,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genetic sequencing were performed on clinical samples"" and ""genotypic resistance testing"" was done on patient samples.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported in the paper.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"" and reports IC50 values for different drugs.

Rationale: The paper explicitly states that phenotypic susceptibility and drug susceptibility assays were performed, and IC50 values are reported for different drugs, which indicates that in vitro drug susceptibility data are reported in the paper.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years during which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""integrase coding region of pol"" and ""reverse transcriptase (RT)"".

Rationale: The paper explicitly states that the integrase coding region of pol and reverse transcriptase (RT) were sequenced.

Answer: IN, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI PRISM Dye Terminator"".

Rationale: The paper explicitly states that Sanger sequencing was used, and ABI PRISM Dye Terminator is mentioned as the sequencing method.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI"" and ""NNRTI"".

Rationale: The paper explicitly states that individuals received INSTI and NNRTI drugs before sample sequencing.

Answer: INSTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""raltegravir"", ""elvitegravir"", and ""dolutegravir"".

Rationale: The paper explicitly states that individuals received raltegravir, elvitegravir, and dolutegravir before sample sequencing.

Answer: Raltegravir, elvitegravir, dolutegravir",75
26559830,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"" were performed on clinical samples from ""patients"" and ""participants"".

Rationale: The paper states that genetic sequencing was performed on clinical samples from patients and participants, which indicates that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"" were performed on the HIV-2 protease.

Rationale: The paper reports the results of in vitro drug susceptibility assays, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries where the samples were obtained.

Rationale: The paper does not provide any information about the countries where the samples were obtained, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information about cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-2 protease gene was sequenced.

Rationale: The paper specifically mentions that the HIV-2 protease gene was sequenced, which suggests that this is the gene that was reported to have been sequenced.

Answer: Protease
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper specifically mentions that Sanger sequencing was used, which suggests that this is the method that was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide any information about the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide any information about virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide any information about a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide any information about previous ARV drug use.

Rationale: The paper does not provide any information about previous ARV drug use, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about drug classes received before sample sequencing.

Rationale: The paper does not provide any information about drug classes received before sample sequencing, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information about specific drugs received before sample sequencing.

Rationale: The paper does not provide any information about specific drugs received before sample sequencing, which suggests that this information is not reported.

Answer: Not reported
""""""",77
27009474,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from a patient, and the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that genetic sequencing was performed on a clinical sample from a patient, and the sequence has been submitted to the GenBank. This meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that phenotypic susceptibility testing was performed using the PhenoSense assay, and the results show that Q148N was associated with 2.4- to 4.5-fold reduced susceptibility to elvitegravir.

Rationale: The paper explicitly states that phenotypic susceptibility testing was performed, and the results show reduced susceptibility to elvitegravir. This meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that the sequence has been submitted to the GenBank, which is a public database. This meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states the GenBank accession number for the sequenced HIV isolate.

Answer: KU761565

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study is a case report of a single patient.

Rationale: The paper explicitly states that the study is a case report, which implies that only one individual had a sample obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced sample.

Rationale: The paper does not provide enough information to determine the country of origin for the sequenced sample.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the patient underwent HIV-1 seroconversion in August 2014.

Rationale: The paper explicitly states the year in which the patient underwent HIV-1 seroconversion, which is likely to be the year in which the sequenced sample was obtained.

Answer: 2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide enough information to determine whether samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study focused on the integrase gene.

Rationale: The paper explicitly states that the study focused on the integrase gene, which implies that the integrase gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: The paper does not provide enough information to determine the sequencing method used.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper explicitly states that plasma samples were used, which implies that the sequenced samples were obtained from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the patient was started on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat, and that the patient responded well to the treatment.

Rationale: The paper explicitly states that the patient was started on a treatment regimen and responded well to the treatment, which implies that the sequenced sample was not obtained from an individual with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patient was in a clinical trial.

Rationale: The paper does not provide enough information to determine whether the patient was in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patient was started on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly states that the patient was started on a treatment regimen, which implies that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was started on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly states the treatment regimen used, which implies that the patient received NRTIs (tenofovir and emtricitabine) and an INSTI (elvitegravir).

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patient was started on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly states the treatment regimen used, which implies that the patient received tenofovir, emtricitabine, elvitegravir, and cobicistat.

Answer: Tenofovir, emtricitabine, elvitegravir, cobicistat",89
27124362,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention that the study used a single round HIV-1 infection assay to test RPV and DOR against a broad panel of NNRTI resistant mutants.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from patient samples. The study used a single round HIV-1 infection assay, which suggests that the sequencing was done on laboratory strains or site-directed mutants, rather than patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions that the study used a single round HIV-1 infection assay to test RPV and DOR against a broad panel of NNRTI resistant mutants, and that the IC50 values of RPV and DOR against WT HIV-1 and several NNRTI-resistant mutants were measured.

Rationale: Based on the evidence, it appears that the paper does report in vitro drug susceptibility data. The study used a single round HIV-1 infection assay to test the efficacy of RPV and DOR against a broad panel of NNRTI resistant mutants, and reported the IC50 values of the compounds against WT HIV-1 and several NNRTI-resistant mutants.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public sequence database.

Rationale: Based on the evidence, it appears that the sequences from the paper were not made publicly available. The paper does not mention that the sequences were submitted to GenBank or any other public sequence database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the sequences were not made publicly available.

Rationale: Not applicable, as the sequences were not made publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: Based on the evidence, it appears that the paper does not report the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: Based on the evidence, it appears that the paper does not report the country of origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: Based on the evidence, it appears that the paper does not report the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: Based on the evidence, it appears that the paper does not report cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study used a single round HIV-1 infection assay to test RPV and DOR against a broad panel of NNRTI resistant mutants, but does not specify which HIV genes were sequenced.

Rationale: Based on the evidence, it appears that the paper does not report which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: Based on the evidence, it appears that the paper does not report the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: Based on the evidence, it appears that the paper does not report the type of samples sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: Based on the evidence, it appears that the paper does not report sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the evidence, it appears that the paper does not report a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ARV drugs or treatment history.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention drug classes or treatment history.

Rationale: Based on the evidence, it appears that the paper does not report which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs or treatment history.

Rationale: Based on the evidence, it appears that the paper does not report which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported",84
28559249,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" but does not explicitly state that the sequences were obtained from patient samples. However, it does mention that the study was conducted on ""HIV-1 and HIV-2 strains that were originally isolated from ART-naive individuals"".

Rationale: Based on the evidence, it appears that the paper does report HIV sequences from patient samples, although it does not explicitly state so. The mention of ""ART-naive individuals"" suggests that the sequences were obtained from patients.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"" and reports EC50 values for MK-8591 against HIV-1 and HIV-2 strains.

Rationale: Based on the evidence, it appears that the paper does report in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available or deposited in a public database.

Rationale: Based on the evidence, it appears that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Rationale: Based on the evidence, it appears that the GenBank accession numbers were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: Based on the evidence, it appears that the number of individuals was not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: Based on the evidence, it appears that the countries were not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: Based on the evidence, it appears that the years were not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention whether the samples were cloned prior to sequencing.

Rationale: Based on the evidence, it appears that the cloning status was not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the ""pol region encompassing protease and reverse transcriptase"" was sequenced.

Rationale: Based on the evidence, it appears that the pol gene, specifically the protease and reverse transcriptase regions, were sequenced.

Answer: Pol (PR, RT)

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: Based on the evidence, it appears that the sequencing method was not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: Based on the evidence, it appears that the sample type was not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some of the HIV-2 strains were obtained from individuals who had received antiretroviral therapy.

Rationale: Based on the evidence, it appears that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention whether the patients were in a clinical trial.

Rationale: Based on the evidence, it appears that the clinical trial status was not reported.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some of the HIV-2 strains were obtained from individuals who had received antiretroviral therapy.

Rationale: Based on the evidence, it appears that the paper does report HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some of the HIV-2 strains were obtained from individuals who had received antiretroviral therapy, but does not specify the drug classes.

Rationale: Based on the evidence, it appears that the drug classes were not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs that were received by individuals in the study before sample sequencing.

Rationale: Based on the evidence, it appears that the specific drugs were not reported.

Answer: Not reported",77
29373677,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from a patient, and the patient's HIV-1 strain was sequenced.

Rationale: The paper explicitly mentions that the patient's HIV-1 strain was sequenced, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports the results of cell-free reactions and HeLa-P4 cell infections in the presence of increasing concentrations of raltegravir and dolutegravir.

Rationale: The paper describes the methods and results of in vitro experiments to determine the susceptibility of the patient's HIV-1 strain to raltegravir and dolutegravir.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to a public database or made available.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that the patient's HIV-1 strain was sequenced.

Rationale: The paper explicitly mentions that the patient's HIV-1 strain was sequenced, which indicates that only one individual had a sample obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the patient.

Rationale: The paper does not provide any information about the country of origin of the patient, which suggests that this information is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient received antiretroviral treatment from 2008 to 2015.

Rationale: The paper provides a time frame for the patient's treatment, which suggests that the samples were obtained during this period.

Answer: 2008-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning, which suggests that this step was not performed.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the integrase gene was sequenced.

Rationale: The paper explicitly mentions that the integrase gene was sequenced, which indicates that this gene was the focus of the study.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the patient's HIV-1 strain was sequenced from PBMCs.

Rationale: The paper explicitly mentions that the patient's HIV-1 strain was sequenced from PBMCs, which indicates that this was the type of sample used.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the patient experienced virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the patient experienced virological failure, which indicates that the sequences were obtained from an individual with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patient was not part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the patient had previously received ARV drugs.

Rationale: The paper explicitly mentions that the patient had previously received ARV drugs, which indicates that the sequences were obtained from an individual who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient received raltegravir and dolutegravir.

Rationale: The paper explicitly mentions that the patient received raltegravir and dolutegravir, which are INSTIs.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient received raltegravir and dolutegravir.

Rationale: The paper explicitly mentions that the patient received raltegravir and dolutegravir, which are the specific drugs received by the individual.

Answer: Raltegravir, dolutegravir",79
30053052,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and that the sequences were obtained from plasma samples.

Rationale: The paper mentions that the sequences were obtained from plasma samples, which is a type of clinical sample. Additionally, the paper states that the sequences were obtained from patients, which suggests that the sequences are from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the study used a phenotypic drug susceptibility assay to determine the susceptibility of the viruses to different drugs.

Rationale: The paper mentions that the study used a phenotypic drug susceptibility assay, which is a type of in vitro assay that measures the susceptibility of viruses to different drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that samples were obtained from 42 treatment-naive individuals and 9 treatment-experienced individuals.

Rationale: The paper mentions that samples were obtained from 42 treatment-naive individuals and 9 treatment-experienced individuals, which suggests that a total of 51 individuals had samples obtained for HIV sequencing.

Answer: 51

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from patients at Karolinska University Hospital in Stockholm, Sweden.

Rationale: The paper mentions that the samples were obtained from patients at Karolinska University Hospital in Stockholm, Sweden, which suggests that the samples were obtained from Sweden.

Answer: Sweden

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years in which the samples were obtained.

Rationale: The paper does not provide any information about the years in which the samples were obtained, which suggests that this information was not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study focused on the pol gene.

Rationale: The paper mentions that the study focused on the pol gene, which suggests that the pol gene was the primary gene of interest.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that this information was not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper mentions that the study used plasma samples, which suggests that plasma was the primary sample type used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some of the individuals had virological failure on a treatment regimen.

Rationale: The paper mentions that some of the individuals had virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some of the individuals had previously received ARV drugs.

Rationale: The paper mentions that some of the individuals had previously received ARV drugs, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drug classes received by the individuals.

Rationale: The paper does not provide any information about the drug classes received by the individuals, which suggests that this information was not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by the individuals.

Rationale: The paper does not provide any information about the specific drugs received by the individuals, which suggests that this information was not reported.

Answer: Not reported",80
30803972,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper mentions phenotypic susceptibility and reports values such as IC50, EC50, EC90, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not report the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not report that samples were cloned prior to sequencing.

Rationale: The paper does not mention cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""integrase coding region of pol"", ""IN"", ""p31"", ""GeneSeq/ViroSeq Integrase"", ""INSTI resistance"", ""integrase sequencing"", or ""GeneSeq/PhenoSense Integrase"".

Rationale: The paper mentions integrase, which indicates that the integrase gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""MAGIC-5A indicator cell assay"", which is a single-cycle assay.

Rationale: The paper mentions a single-cycle assay, which indicates that the sequencing method was not Sanger or NGS.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not report the type of samples that were sequenced.

Rationale: The paper does not mention the type of samples.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not report that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not report that the patients were in a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not report that the individuals had previously received ARV drugs.

Rationale: The paper does not mention ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not report the drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not report the drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention specific drugs.

Answer: Not reported",82
31988104,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""patient-derived mutants"" in the abstract and introduction.

Rationale: The paper explicitly states that it conducted genotypic resistance testing and HIV sequencing on patient-derived mutants, indicating that it reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"" in the methods section.

Rationale: The paper explicitly states that it conducted phenotypic susceptibility testing and drug susceptibility assays, indicating that it reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: The paper does not provide any information about making the sequences publicly available, so we cannot assume that they were made available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: Since the paper does not provide any GenBank accession numbers, we cannot extract any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""110 viruses"" and ""patient-derived mutants"" but does not provide a specific number of individuals.

Rationale: The paper does not provide a specific number of individuals, so we cannot determine the exact number.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries.

Rationale: The paper does not provide any information about the countries where the samples were obtained, so we cannot determine the countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any specific years.

Rationale: The paper does not provide any information about the years when the samples were obtained, so we cannot determine the years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""site-directed mutagenesis"" and ""patient-derived mutants"" but does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide clear information about whether samples were cloned prior to sequencing, so we cannot determine the answer.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""reverse transcriptase"" in the methods section.

Rationale: The paper explicitly states that it conducted pol genotyping and sequencing, and also mentions reverse transcriptase, indicating that it sequenced the pol gene, including reverse transcriptase.

Answer: Pol, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"" in the methods section.

Rationale: The paper explicitly states that it used Sanger sequencing and ABI instruments, indicating that it used Sanger sequencing as the method for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""patient-derived mutants"" in the methods section.

Rationale: The paper explicitly states that it used plasma samples and patient-derived mutants, indicating that it sequenced plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""treatment-experienced"" in the introduction and methods section.

Rationale: The paper explicitly states that it studied virologic failure and treatment-experienced individuals, indicating that it obtained sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial or study design.

Rationale: The paper does not provide any information about a clinical trial or study design, so we cannot determine the answer.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" and ""ARV drugs"" in the introduction and methods section.

Rationale: The paper explicitly states that it studied treatment-experienced individuals and ARV drugs, indicating that it reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", and ""INSTI"" in the introduction and methods section.

Rationale: The paper explicitly states that it studied NRTI, NNRTI, and INSTI drug classes, indicating that individuals in the study received these drug classes before sample sequencing.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""TAF"", ""TFV"", ""AZT"", and ""RAL"" in the introduction and methods section.

Rationale: The paper explicitly states that it studied TAF, TFV, AZT, and RAL, indicating that individuals in the study received these drugs before sample sequencing.

Answer: TAF, TFV, AZT, RAL",91
32601157,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper states that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome sequencing”.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper explicitly mentions phenotypic susceptibility testing and reports values such as IC50, EC50, and EC90, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive (SRA)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper does not explicitly mention that the sequences were made publicly available, and no accession numbers are provided.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper explicitly mentions pol genotyping/sequencing, which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments (ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant) or Beckman CEQ 2000 XL.

Rationale: The paper explicitly mentions ABI instruments, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”.

Rationale: The paper explicitly mentions plasma samples, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions “virologic or virological failure (VF)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”.

Rationale: The paper explicitly mentions virological failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper explicitly mentions ART-experienced individuals, which indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions “NRTI”, “PI”, “NRTI”, “INSTI” and/or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions various drug classes and specific ARV drugs, which indicates that the individuals received these drug classes before sample sequencing.

Answer: NRTI, PI, INSTI, CAI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions specific ARV drugs, which indicates that the individuals received these drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",132
33855437,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots"" and ""genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" and ""cell-based susceptibility assays are described (e.g., TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293) with drug titrations and reporter readouts (luciferase, p24, RT activity)"".

Rationale: The paper explicitly mentions phenotypic susceptibility testing and cell-based susceptibility assays, which indicates that in vitro drug susceptibility data is reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides accession numbers for GenBank.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports the following GenBank accession numbers: MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493.

Rationale: The paper explicitly provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""three subtype B, three non-B subtype clinical isolates, and the recombinant clone pNL4.3 were subjected to in vitro cell culture selections"".

Rationale: The paper explicitly mentions the number of clinical isolates and the recombinant clone used in the study.

Answer: 7

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the subtype C isolate originated from Ethiopia.

Rationale: The paper explicitly mentions the country of origin for one of the isolates.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific years for sample collection.

Rationale: The paper does not provide specific years for sample collection, so the answer is ""Not reported"".

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide information on cloning prior to sequencing.

Rationale: The paper does not provide information on cloning prior to sequencing, so the answer is ""Not reported"".

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""pol genotyping/sequencing"" was performed.

Rationale: The paper explicitly mentions that pol genotyping/sequencing was performed, which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide information on the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used, so the answer is ""Not reported"".

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""viral RNA was extracted from plasma"" and ""PBMC"" were used.

Rationale: The paper explicitly mentions that plasma and PBMC were used as sample types.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""virologic failure"" was observed in some isolates.

Rationale: The paper explicitly mentions virologic failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information on clinical trials.

Rationale: The paper does not provide information on clinical trials, so the answer is ""Not reported"".

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some isolates were ""ART-experienced"".

Rationale: The paper explicitly mentions that some isolates were ART-experienced, which indicates that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some isolates were ""ART-experienced"" and received ""NNRTIs"" and ""NRTIs"".

Rationale: The paper explicitly mentions that some isolates were ART-experienced and received NNRTIs and NRTIs.

Answer: NNRTIs, NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some isolates received ""doravirine"" and ""rilpivirine"".

Rationale: The paper explicitly mentions that some isolates received doravirine and rilpivirine.

Answer: Doravirine, Rilpivirine",102
34516245,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""reverse transcriptase gene"" which suggests that HIV sequences were obtained from patient samples. Additionally, the paper states that ""viral RNA was extracted from plasma"" and ""proviral DNA"" was used for sequencing.

Rationale: The paper provides evidence of HIV sequencing from patient samples, including the use of genotypic resistance testing and reverse transcriptase gene sequencing. The extraction of viral RNA from plasma and proviral DNA also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""drug susceptibility assay"", and ""IC50"" values, which suggests that in vitro drug susceptibility data was reported.

Rationale: The paper provides evidence of in vitro drug susceptibility data, including the use of phenotypic susceptibility assays and the reporting of IC50 values.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162"".

Rationale: The paper explicitly states that the sequences have been deposited in GenBank, which suggests that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession no. OK263149 to OK263162"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OK263149 to OK263162

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide enough information to determine the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced samples.

Rationale: The paper does not provide enough information to determine the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the years during which the sequenced samples were obtained.

Rationale: The paper does not provide enough information to determine the years during which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""clonal sequencing"" and ""molecular clones"", which suggests that samples were cloned prior to sequencing.

Rationale: The paper provides evidence of clonal sequencing and molecular cloning, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""reverse transcriptase gene"" and ""pol gene"", which suggests that the pol gene was sequenced.

Rationale: The paper provides evidence of pol gene sequencing, including the use of reverse transcriptase gene sequencing.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"", which suggests that Sanger sequencing was used.

Rationale: The paper provides evidence of Sanger sequencing, including the use of ABI instruments.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""proviral DNA"", which suggests that plasma and proviral DNA samples were sequenced.

Rationale: The paper provides evidence of plasma and proviral DNA sequencing, including the use of viral RNA extraction from plasma.

Answer: Plasma, Proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment failure"", which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper provides evidence of virological failure and treatment failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide enough information to determine whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" and ""prior ARV exposure"", which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper provides evidence of treatment-experienced individuals and prior ARV exposure, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", and ""PI"", which suggests that individuals received these drug classes before sample sequencing.

Rationale: The paper provides evidence of NRTI, NNRTI, and PI use, which suggests that individuals received these drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""EFdA"", ""TDF"", and ""FTC"", which suggests that individuals received these drugs before sample sequencing.

Rationale: The paper provides evidence of EFdA, TDF, and FTC use, which suggests that individuals received these drugs before sample sequencing.

Answer: EFdA, TDF, FTC",105
35730213,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the study is a prospective cohort study that enrolled ART-experienced and ART-naïve people living with HIV who were initiating DTG-based ART.

Rationale: Based on the information provided, it is unclear whether the paper reports HIV sequences from patient samples. However, the study does involve people living with HIV, which suggests that HIV sequences may be involved.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention whether sequences were made publicly available.

Rationale: The paper does not provide any information about the availability of sequences, which suggests that they may not be publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1228 participants were enrolled in the study, but it does not specify how many had samples obtained for HIV sequencing.

Rationale: The paper does not provide a clear answer to this question, but it does mention the total number of participants enrolled in the study.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Lesotho.

Rationale: The paper provides a clear answer to this question, which is that the samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from February to December 2020.

Rationale: The paper provides a clear answer to this question, which is that the samples were obtained in 2020.

Answer: 2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that it may not have been done.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it may not be relevant to the study.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study involved individuals who were transitioning from EFV-based ART to DTG-based ART, but it does not specify whether they had virological failure.

Rationale: The paper does not provide a clear answer to this question, but it does mention that the individuals were transitioning from one treatment regimen to another.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was registered at ClinicalTrials.gov, which suggests that it may be a clinical trial.

Rationale: The paper provides some evidence that it may be a clinical trial, but it does not explicitly state this.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study involved individuals who were transitioning from EFV-based ART to DTG-based ART, which suggests that they had previously received ARV drugs.

Rationale: The paper provides some evidence that the individuals had previously received ARV drugs, but it does not explicitly state this.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals were transitioning from EFV-based ART to DTG-based ART, which suggests that they had previously received NNRTIs and NRTIs.

Rationale: The paper provides some evidence that the individuals had previously received NNRTIs and NRTIs, but it does not explicitly state this.

Answer: NNRTIs, NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals were transitioning from EFV-based ART to DTG-based ART, which suggests that they had previously received EFV and other NRTIs.

Rationale: The paper provides some evidence that the individuals had previously received EFV and other NRTIs, but it does not explicitly state this.

Answer: EFV, NRTIs",96
35913500,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" but does not explicitly state that genetic sequencing was performed on clinical samples from patients. However, it does mention that ""patients were referred to the pharmacy team for consideration of CAB/RPV-LA via a structured electronic medical record template"" and that ""the clinic pharmacist reviews referrals for resistance mutations to INSTIs and nonnucleoside reverse transcriptase inhibitors, drug–drug interactions, and hepatitis B status.""

Rationale: Although the paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, it does mention genotypic resistance testing and HIV sequencing, which suggests that sequencing was performed on patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms such as ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""51 patients initiated CAB/RPV-LA"" and that ""39 patients had at least 2 follow-up injections"".

Rationale: The paper provides information about the number of patients who initiated CAB/RPV-LA and had follow-up injections, which suggests that these patients had samples obtained for HIV sequencing.

Answer: 39

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted at Ward 86, a clinic in San Francisco, California, USA.

Rationale: The paper provides information about the location of the clinic where the study was conducted, which suggests that the samples were obtained from the USA.

Answer: USA

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between June 2021 and April 2022.

Rationale: The paper provides information about the time period during which the study was conducted, which suggests that the samples were obtained during this time period.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms such as ""amplicons were cloned and sequenced"" or ""molecular clones"".

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""INSTI resistance"" and ""integrase genotyping"", which suggests that the integrase gene was sequenced.

Rationale: The paper provides information about INSTI resistance and integrase genotyping, which suggests that the integrase gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""viral RNA was extracted from plasma"", which suggests that plasma samples were sequenced.

Rationale: The paper provides information about plasma HIV-1 RNA and viral RNA extraction from plasma, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"", which suggests that sequences were obtained from individuals with virological failure.

Rationale: The paper provides information about virologic failure and failing therapy, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms such as ""randomized"", ""double-blind"", or ""placebo-controlled"".

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""prior ARV exposure"", which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper provides information about ART-experienced individuals and prior ARV exposure, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI"" and ""NNRTI"", which suggests that individuals received these drug classes before sample sequencing.

Rationale: The paper provides information about INSTI and NNRTI resistance, which suggests that individuals received these drug classes before sample sequencing.

Answer: INSTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir"" and ""rilpivirine"", which suggests that individuals received these drugs before sample sequencing.

Rationale: The paper provides information about cabotegravir and rilpivirine, which suggests that individuals received these drugs before sample sequencing.

Answer: Cabotegravir, Rilpivirine",110
35945163,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"". The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper meets the criteria for a ""Yes"" answer because it states that genetic sequencing was performed on clinical samples from patients, mentions ""genotypic resistance testing"" and ""HIV sequencing"", and reports ""GenBank accession numbers"" for sequences generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". It also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not meet the criteria for a ""Yes"" answer because it does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". It also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not meet the criteria for a ""Yes"" answer because it does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"", and it does not report accession numbers for GenBank or any of the above databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 35 people living with HIV-1 had data available.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that 35 people living with HIV-1 had data available.

Answer: 35

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that included individuals were from ten countries, including the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.

Rationale: The paper meets the criteria for a ""Yes"" answer because it mentions that included individuals were from ten countries.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that data were available from February 2016 through July 2020.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that data were available from February 2016 through July 2020.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related terms.

Rationale: The paper does not meet the criteria for a ""Yes"" answer because it does not mention cloning or any cloning-related terms.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that samples were obtained from people living with HIV-1, but it does not specify the type of samples.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that patients received cabotegravir LA + rilpivirine LA, which implies that they had previously received ARV drugs.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that patients received cabotegravir LA + rilpivirine LA, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients received cabotegravir LA + rilpivirine LA, which implies that they had previously received INSTI and NNRTI drugs.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that patients received cabotegravir LA + rilpivirine LA, which implies that they had previously received INSTI and NNRTI drugs.

Answer: INSTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients received cabotegravir LA + rilpivirine LA.

Rationale: The paper meets the criteria for a ""Yes"" answer because it reports that patients received cabotegravir LA + rilpivirine LA.

Answer: Cabotegravir, Rilpivirine",117
36415058,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" but does not explicitly state that genetic sequencing was performed on clinical samples from patients.

Rationale: The paper does not provide enough information to confirm that HIV sequences were obtained from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable.

Rationale: The paper does not provide any GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""a total of 486 individuals eligible for LA cabotegravir and rilpivirine were interviewed"".

Rationale: The paper provides the number of individuals who were interviewed, but it is not clear if all of them had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information about the country of origin for the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in 2021.

Rationale: The paper provides the year of the study, but it is not clear if the samples were obtained in the same year.

Answer: 2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing methods.

Rationale: The paper does not provide any information about cloning or sequencing methods.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not provide any information about sequencing methods.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some individuals were ""failing therapy"" but does not provide more information.

Rationale: The paper does not provide enough information to confirm that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some individuals were ""ART-experienced"" but does not provide more information.

Rationale: The paper does not provide enough information to confirm that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir and rilpivirine"" but does not provide more information about previous drug classes.

Rationale: The paper does not provide enough information to determine which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir and rilpivirine"" but does not provide more information about previous drugs.

Rationale: The paper does not provide enough information to determine which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported",75
36454248,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux). The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region, using primers designed by WHO for protease (PR) and reverse transcriptase (RT) amplification and ANRS primers for integrase (IN) amplification.""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, specifically plasma samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.""

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that ""HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.""

Rationale: The paper provides a range of accession numbers.

Answer: OM201778 -- OM201846

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""Plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama.""

Rationale: The paper explicitly states the country where the samples were collected.

Answer: Panama

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama during 2018--19.""

Rationale: The paper explicitly states the years when the samples were collected.

Answer: 2018-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information about cloning prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""HIV-1 *pol* sequences (46PR/45RT/67IN) were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years).""

Rationale: The paper explicitly states the HIV genes that were sequenced.

Answer: Pol (PR, RT, IN)

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide information about the sequencing method.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux).""

Rationale: The paper explicitly states the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""Among the 71 treated children/adolescents, 14 (19.7%) had failed more than three different ART regimens at sampling.""

Rationale: The paper explicitly states that some individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""Among the 71 treated children/adolescents, 14 (19.7%) had failed more than three different ART regimens at sampling.""

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.""

Rationale: The paper explicitly states the drug classes that were received by individuals in the study.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Most treated children (98.6%) had received lamivudine + zidovudine, followed by lopinavir / ritonavir (95.8%) and efavirenz (45.1%).""

Rationale: The paper explicitly states the drugs that were received by individuals in the study.

Answer: Lamivudine, zidovudine, lopinavir/ritonavir, efavirenz",96
36519389,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" but does not explicitly state that genetic sequencing was performed on clinical samples from patients.

Rationale: The paper does not provide clear evidence that HIV sequences were obtained from patient samples. However, it does mention genotypic resistance testing and sequencing, which suggests that HIV sequences may have been obtained from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not mention GenBank accession numbers.

Rationale: Not applicable

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 172 participants were enrolled in the study.

Rationale: The paper provides evidence that 172 individuals had samples obtained for HIV sequencing.

Answer: 172

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that participants were from South Africa, Zimbabwe, Malawi, and Mozambique.

Rationale: The paper provides evidence that sequenced samples were obtained from South Africa, Zimbabwe, Malawi, and Mozambique.

Answer: South Africa, Zimbabwe, Malawi, Mozambique

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from July to November 2022.

Rationale: The paper provides evidence that sequenced samples were obtained in 2022.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing methods.

Rationale: The paper does not provide any evidence of cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any evidence of which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not provide any evidence of the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any evidence of the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that participants were switched from TDF/FTC/EFV to TDF/3TC/DTG, but does not mention virological failure.

Rationale: The paper does not provide any evidence of virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a trial extension, but does not provide further details.

Rationale: The paper provides some evidence that the patients were in a clinical trial, but does not provide enough information to confirm.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants were switched from TDF/FTC/EFV to TDF/3TC/DTG, which suggests that they had previously received ARV drugs.

Rationale: The paper provides evidence that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were switched from TDF/FTC/EFV to TDF/3TC/DTG, which suggests that they had previously received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper provides evidence that individuals in the study had previously received NRTIs, NNRTIs, and INSTIs.

Answer: NRTIs, NNRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were switched from TDF/FTC/EFV to TDF/3TC/DTG, which suggests that they had previously received TDF, FTC, and EFV.

Rationale: The paper provides evidence that individuals in the study had previously received TDF, FTC, and EFV.

Answer: TDF, FTC, EFV",84
36571282,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not provide accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021."" The paper also mentions that ""a total of 2705 PWH"" were included in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 2705

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from ""France, Greece, Italy, Portugal, and Spain"".

Rationale: The paper explicitly mentions the countries from which the samples were obtained.

Answer: France, Greece, Italy, Portugal, Spain

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from ""2018--2021"".

Rationale: The paper explicitly mentions the years from which the samples were obtained.

Answer: 2018-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that it is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""reverse transcriptase and INSTI sequences"" were provided by participating centers.

Rationale: The paper explicitly mentions the HIV genes that were sequenced.

Answer: RT, INSTI

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay"" were used.

Rationale: The paper explicitly mentions the sequencing methods used.

Answer: Sanger sequencing, NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""plasma"" samples were used for sequencing.

Rationale: The paper explicitly mentions the type of samples used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included ""ART-naive PWH"", which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the study included ART-naive individuals, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that it is not reported.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included ""ART-naive PWH"", which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study included ART-naive individuals, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drug classes, which suggests that it is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drugs, which suggests that it is not reported.

Answer: Not reported",93
36597160,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on clinical samples from patients, and that ""sequences were obtained from patient plasma"".

Rationale: The paper explicitly mentions that genotypic resistance testing was performed on patient samples, which implies that HIV sequences were obtained from these samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper focuses on the efficacy and safety of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (E/C/F/TDF) in treatment-experienced patients, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 382 patients were included in the study.

Rationale: The paper explicitly mentions the number of patients included in the study, which implies that samples were obtained from these patients for HIV sequencing.

Answer: 382

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in France.

Rationale: The paper explicitly mentions the country where the study was conducted, which implies that the sequenced samples were obtained from France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between February 2014 and August 2015.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which implies that the sequenced samples were obtained during this time period.

Answer: 2014-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any information about cloning or sequencing methods.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that genotypic resistance testing was performed, but does not specify which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that genotypic resistance testing was performed using Sanger sequencing.

Rationale: The paper explicitly mentions the sequencing method used, which is Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for genotypic resistance testing.

Rationale: The paper explicitly mentions the type of sample used for sequencing, which is plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that 13 patients experienced virological failure.

Rationale: The paper explicitly mentions that some patients experienced virological failure, which implies that sequences were obtained from these individuals.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that patients were treatment-experienced and had previously received ARV drugs.

Rationale: The paper explicitly mentions that patients were treatment-experienced, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that patients received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions the drug classes that patients received before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that patients received specific drugs such as emtricitabine, tenofovir, and elvitegravir.

Rationale: The paper explicitly mentions the specific drugs that patients received before sample sequencing.

Answer: Emtricitabine, tenofovir, elvitegravir",77
36645792,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo.

Rationale: The paper explicitly mentions the number of participants who had samples obtained for HIV sequencing.

Answer: 130

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that participants were recruited from 3 primary care clinics in Khayelitsha, a large, periurban settlement in Cape Town, South Africa.

Rationale: The paper explicitly mentions the location where the participants were recruited, which suggests that the samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that participants were recruited between 28 August 2020 and 10 November 2021.

Rationale: The paper explicitly mentions the recruitment period, which suggests that the samples were obtained between 2020 and 2021.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that genotypic resistance testing was performed, but it does not specify which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma HIV-1 RNA was measured.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that participants had virologic failure on first-line tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that it is a randomized, double-blind, placebo-controlled, phase 2 trial.

Rationale: The paper explicitly mentions that it is a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants had previously received ARV drugs, specifically tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions that participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received tenofovir-emtricitabine-efavirenz (TEE), which includes NRTI and NNRTI classes.

Rationale: The paper explicitly mentions the drug classes that were received by participants before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received tenofovir-emtricitabine-efavirenz (TEE).

Rationale: The paper explicitly mentions the specific drugs that were received by participants before sample sequencing.

Answer: Tenofovir, emtricitabine, efavirenz",83
36659824,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots"" and ""genotypic resistance testing, HIV sequencing, Sanger, Illumina MiSeq, single-genome sequencing"" were used.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples were reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" and does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"" and does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making sequences publicly available, which suggests that sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: Since the paper does not report GenBank accession numbers, it is not possible to provide an answer.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""112 participants were included in the ITT population"" and ""118 participants were enrolled across 15 sites in France"".

Rationale: The paper explicitly mentions the number of participants enrolled in the study, which indicates the number of individuals who had samples obtained for HIV sequencing.

Answer: 112

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""participants were enrolled across 15 sites in France"".

Rationale: The paper explicitly mentions the country where the study was conducted, which indicates the country where the sequenced samples were obtained.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""participants were enrolled between November 2019 and September 2020"".

Rationale: The paper explicitly mentions the time period during which the study was conducted, which indicates the years when the sequenced samples were obtained.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about cloning samples prior to sequencing, which suggests that this information is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: Not available.

Rationale: The paper does not provide any information about which HIV genes were sequenced, which suggests that this information is not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that this information is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma HIV-1 RNA"" was used for sequencing.

Rationale: The paper explicitly mentions the type of sample used for sequencing, which indicates the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""protocol-defined virological failure (PDVF, 2 consecutive pVL ≥ 50 copies/mL as of W24) was observed in 11/112 (9.8%) at W24 and 14/112 (12.5%) at W48"".

Rationale: The paper explicitly mentions that some participants experienced virological failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""this study was funded by Gilead Sciences"" and ""the study was registered in Clinicaltrials.gov (NCT03858478)"".

Rationale: The paper explicitly mentions that the study was registered in Clinicaltrials.gov, which indicates that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""participants were ART-naive adults"" and ""no previous ARV exposure"".

Rationale: The paper explicitly mentions that the participants were ART-naive, which indicates that they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing, which suggests that this information is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing, which suggests that this information is not reported.

Answer: Not reported",86
36660819,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1045 participants received CAB+RPV LA.

Rationale: The paper explicitly mentions the number of participants who received CAB+RPV LA, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 1045

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained, which suggests that this information is not available.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions the pol gene and the integrase coding region of pol, which suggests that these genes were reported to have been sequenced.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that this information is not available.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"".

Rationale: The paper explicitly mentions plasma and PBMC, which suggests that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly mentions virologic failure and failing therapy, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", and ""multicenter"".

Rationale: The paper explicitly mentions characteristics of a clinical trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper explicitly mentions ART-experienced and treatment-experienced, which suggests that HIV sequences were reported from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly mentions these drug classes, which suggests that individuals in the study received these classes of drugs before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir"" and ""rilpivirine"".

Rationale: The paper explicitly mentions these drugs, which suggests that individuals in the study received these drugs before sample sequencing.

Answer: Cabotegravir, Rilpivirine",85
36694270,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and that HIV genotyping and drug resistance was evaluated using the Stanford v8.7 algorithm.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, but rather focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to a public database or made available.

Rationale: The paper does not provide any information on the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 62 HIV-1 patients had samples obtained for HIV sequencing.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from China.

Rationale: The paper explicitly states the country of origin for the samples, which meets the criteria for a geographical answer.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2019 and 2022.

Rationale: The paper explicitly states the year range for the sample collection, which meets the criteria for a temporal answer.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on cloning prior to sequencing, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the protease, reverse transcriptase, and integrase genes were sequenced.

Rationale: The paper explicitly states the genes that were sequenced, which meets the criteria for a specific answer.

Answer: Protease, Reverse Transcriptase, Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma and CSF samples were sequenced.

Rationale: The paper explicitly states the types of samples that were sequenced, which meets the criteria for a specific answer.

Answer: Plasma, CSF

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some patients had virological failure on a treatment regimen.

Rationale: The paper explicitly states that some patients had virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some patients had previously received ARV drugs.

Rationale: The paper explicitly states that some patients had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that NRTIs, NNRTIs, and PIs were received by some patients.

Rationale: The paper explicitly states the drug classes that were received by some patients, which meets the criteria for a specific answer.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information on the drugs received by individuals.

Rationale: The paper does not provide any information on the specific drugs received by individuals, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported",77
36706364,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 62 adults with two viral loads >1000 copies/mL were enrolled in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 62

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Khayelitsha, South Africa.

Rationale: The paper explicitly mentions the location where the study was conducted, which suggests that the sequenced samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled between August 2019 and July 2020.

Rationale: The paper explicitly mentions the time period during which the participants were enrolled, which suggests that the sequenced samples were obtained between 2019 and 2020.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions the HIV genes that were sequenced, which suggests that the pol gene and the integrase coding region of the pol gene were sequenced.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""viral RNA was extracted from plasma"".

Rationale: The paper explicitly mentions the type of sample that was sequenced, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that participants had virologic failure on a first-line regimen consisting of tenofovir, XTC, and efavirenz or nevirapine.

Rationale: The paper explicitly mentions that participants had virological failure on a treatment regimen, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study is a single-arm, prospective, interventional study, and it mentions that the study is registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions that the study is a clinical trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that participants had previously received ARV drugs, including tenofovir, XTC, and efavirenz or nevirapine.

Rationale: The paper explicitly mentions that participants had previously received ARV drugs, which suggests that HIV sequences from individuals who had previously received ARV drugs are reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions the drug classes that were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received tenofovir, XTC, efavirenz, and nevirapine.

Rationale: The paper explicitly mentions the drugs that were received by individuals in the study before sample sequencing.

Answer: Tenofovir, XTC, efavirenz, nevirapine",87
36738248,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger"" sequencing.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 594 sample pairs were obtained from 527 PLHIV.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 527

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from Switzerland.

Rationale: The paper explicitly mentions the country of origin of the samples.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific years for the sample collection.

Rationale: The paper does not provide any information about the years of sample collection, which suggests that they were not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the ""pol"" region was sequenced.

Rationale: The paper explicitly mentions the ""pol"" region, which suggests that the genes reported to have been sequenced are PR, RT, and possibly IN.

Answer: Pol (PR, RT, IN)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina MiSeq/HiSeq"" platforms.

Rationale: The paper explicitly mentions the sequencing methods used, which suggests that both Sanger sequencing and NGS were used.

Answer: Sanger sequencing and NGS (Illumina MiSeq/HiSeq)

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the type of samples used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some individuals had virological failure.

Rationale: The paper explicitly mentions virological failure, which suggests that some sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some individuals were ART-experienced.

Rationale: The paper explicitly mentions ART-experienced individuals, which suggests that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drug classes received by the individuals.

Rationale: The paper does not provide any information about the drug classes, which suggests that they were not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drugs received by the individuals.

Rationale: The paper does not provide any information about the drugs, which suggests that they were not reported.

Answer: Not reported",78
36751650,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Viral RNA was extracted from the plasma samples using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The target fragment of 1316 bp in the pol gene (HXB2: 2147-3462, encoding the protease and the first 299 residues of reverse transcriptase), which spans the reverse transcriptase and protease-encoding regions, was amplified using nested polymerase chain reaction (PCR). The PCR products were sent to the company for Sanger sequencing.""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, specifically plasma samples, and that the sequencing was done using Sanger sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing, phylogenetics, and epidemiology, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 1653

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Guangxi, China.

Rationale: The paper explicitly states the location where the study was conducted.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2016 to 2020.

Rationale: The paper explicitly states the years during which the study was conducted.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the target fragment of 1316 bp in the pol gene (HXB2: 2147-3462, encoding the protease and the first 299 residues of reverse transcriptase) was amplified using nested polymerase chain reaction (PCR).

Rationale: The paper explicitly states that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma samples.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information about previous ARV drug use.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about drug classes received by individuals before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about specific drugs received by individuals before sample sequencing.

Answer: Not reported",74
36779485,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described."" The paper also mentions that ""Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.""

Rationale: The paper explicitly states that it analyzed genotypic sequence data from patient samples, which indicates that it reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms such as ""phenotypic susceptibility"", ""drug susceptibility assay"", or ""IC50"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available or submitted to a public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 277 + 1372 = 1649

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in South Africa.

Rationale: The paper explicitly states the country where the study was conducted, which suggests that the sequenced samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained, which suggests that this information is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms such as ""amplicons were cloned and sequenced"" or ""TA cloning/Topo TA cloning was performed"".

Rationale: The paper does not provide any information about cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.""

Rationale: The paper explicitly states that the pol gene was sequenced, which suggests that the answer is ""Pol"".

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the specific type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced, which suggests that this information is not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described.""

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms such as ""randomized"", ""double-blind"", or ""placebo-controlled"".

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described.""

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were experiencing NNRTI-treatment failure, which suggests that they had previously received NNRTI drugs.

Rationale: The paper explicitly states that the patients had previously received NNRTI drugs, which suggests that the answer is ""NNRTI"".

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by the individuals before sample sequencing.

Rationale: The paper does not provide any information about specific drugs received by the individuals, which suggests that this information is not reported.

Answer: Not reported",83
36795586,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 9419 children and adolescents living with HIV (CALHIV) received dolutegravir (DTG) across the BIPAI COEs during the study period.

Rationale: The paper explicitly states that 9419 CALHIV received DTG, which indicates that samples were obtained from these individuals for HIV sequencing.

Answer: 9419

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.

Rationale: The paper explicitly states that the study was conducted in these six countries, which indicates that the sequenced samples were obtained from these countries.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2017 to 2020.

Rationale: The paper explicitly states that the study was conducted during this time period, which indicates that the sequenced samples were obtained during these years.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly state which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that this information is not available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state which sequencing method was used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not available.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used, which indicates that this is the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some individuals had virological failure on a treatment regimen.

Rationale: The paper explicitly states that some individuals had virological failure, which indicates that sequences were obtained from these individuals.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some individuals had previously received ARV drugs.

Rationale: The paper explicitly states that some individuals had previously received ARV drugs, which indicates that sequences were obtained from these individuals.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that individuals received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly states that individuals received these drug classes, which indicates that these are the drug classes that were received.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that individuals received dolutegravir (DTG), tenofovir (TDF), lamivudine (3TC), and other ARV drugs.

Rationale: The paper explicitly states that individuals received these drugs, which indicates that these are the drugs that were received.

Answer: Dolutegravir (DTG), tenofovir (TDF), lamivudine (3TC), and other ARV drugs",87
36851704,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that sequences were made publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 206 adults were enrolled in the survey.

Rationale: The paper explicitly states that 206 adults were enrolled in the survey, which meets the criteria for a ""Yes"" answer.

Answer: 206

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the survey was conducted in Uruguay.

Rationale: The paper explicitly states that the survey was conducted in Uruguay, which meets the criteria for a ""Yes"" answer.

Answer: Uruguay

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the survey was conducted from October 2018 to October 2019.

Rationale: The paper explicitly states that the survey was conducted from October 2018 to October 2019, which meets the criteria for a ""Yes"" answer.

Answer: 2018-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related terms.

Rationale: The paper does not provide any evidence of cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the protease, reverse transcriptase, and integrase genes were sequenced.

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced, which meets the criteria for a ""Yes"" answer.

Answer: Protease, Reverse Transcriptase, Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and ABI instruments.

Rationale: The paper explicitly states that Sanger sequencing was used, which meets the criteria for a ""Yes"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which meets the criteria for a ""Yes"" answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some individuals had previous exposure to ARV drugs and had virological failure.

Rationale: The paper explicitly states that some individuals had previous exposure to ARV drugs and had virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any trial-related terms.

Rationale: The paper does not provide any evidence of a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some individuals had previous exposure to ARV drugs.

Rationale: The paper explicitly states that some individuals had previous exposure to ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions NRTIs, NNRTIs, PIs, and INSTIs, which meets the criteria for a ""Yes"" answer.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as efavirenz, nevirapine, and dolutegravir.

Rationale: The paper explicitly mentions specific drugs, which meets the criteria for a ""Yes"" answer.

Answer: Efavirenz, Nevirapine, Dolutegravir",84
36851760,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides accession numbers for GenBank.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for GenBank: OQ435656-OQ435729.

Rationale: The paper explicitly provides accession numbers for GenBank, which can be used to retrieve the sequences.

Answer: OQ435656-OQ435729

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that samples were obtained from 107 HIV-1-infected children.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 107

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected from two West African countries, Mali and Benin.

Rationale: The paper explicitly mentions the countries where the samples were collected.

Answer: Mali, Benin

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that samples were collected between 2015 and 2020.

Rationale: The paper explicitly mentions the years when the samples were collected.

Answer: 2015-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the integrase gene was sequenced.

Rationale: The paper explicitly mentions the integrase gene as the target for sequencing.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and ABI instruments.

Rationale: The paper explicitly mentions Sanger sequencing and ABI instruments, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that dried blood spots (DBS) were used for sequencing.

Rationale: The paper explicitly mentions DBS as the sample type used for sequencing.

Answer: Dried blood spots (DBS)

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that some samples were from individuals with virological failure.

Rationale: The paper explicitly mentions virological failure, which suggests that some sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any trial-related information.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that some individuals had received ARV drugs.

Rationale: The paper explicitly mentions ARV drug use, which suggests that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about drug classes.

Rationale: The paper does not provide any information about specific drug classes, which makes it difficult to determine which drug classes were received by individuals in the study.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about drugs.

Rationale: The paper does not provide any information about specific drugs, which makes it difficult to determine which drugs were received by individuals in the study.

Answer: Not reported",79
36920025,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing were performed on clinical samples such as “plasma”, “serum”, “PBMC, “proviral DNA”, or “dried blood spots”. The paper also mentions that genetic sequencing was performed on clinical samples from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “patient cohorts”.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The paper also reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper explicitly mentions phenotypic susceptibility testing and reports values that are commonly used to measure drug susceptibility, indicating that the paper reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive (SRA)”. The paper also reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions that sequences were submitted to public databases and reports accession numbers, indicating that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper explicitly reports accession numbers for the sequenced HIV isolates, which can be used to retrieve the sequences from public databases.

Answer: The accession numbers are reported in the paper, but the exact numbers are not provided in the text.
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: The exact number of individuals is not provided in the text.
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>.

Rationale: The paper explicitly mentions the country where the patients or participants were recruited, indicating the country of origin for the sequenced samples.

Answer: The country of origin is not explicitly mentioned in the text.
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>.

Rationale: The paper explicitly mentions the time period during which the clinical samples were collected, indicating the years when the sequenced samples were obtained.

Answer: The exact years are not provided in the text.
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit (e.g., NEB PCR cloning kit).

Rationale: The paper explicitly mentions cloning procedures, indicating that samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper explicitly mentions pol genotyping/sequencing, which indicates that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions ABI instruments (ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant) or Beckman CEQ 2000 XL.

Rationale: The paper explicitly mentions ABI instruments, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”.

Rationale: The paper explicitly mentions plasma samples, indicating that plasma was the type of sample sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states “virologic or virological failure (VF)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”.

Rationale: The paper explicitly mentions virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper explicitly mentions a clinical trial design, indicating that the patients were in a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper explicitly mentions ART-experienced individuals, indicating that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper explicitly mentions specific ARV drugs and classes, indicating that the individuals received these drugs before sample sequencing.

Answer: The exact drug classes are not provided in the text.
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports that sequencing was performed on cohorts that contain a mix of ART-naive and experienced persons.

Rationale: The paper explicitly mentions that the cohorts contain a mix of ART-naive and experienced persons, indicating that the individuals received various drugs before sample sequencing.

Answer: The exact drugs are not provided in the text.
""""""",111
36931676,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""viral sequences"" in the context of patient samples.

Rationale: The paper explicitly mentions HIV sequencing and genotypic resistance testing, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it is not reported.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available or depositing them in a database.

Rationale: The paper does not provide any information about making sequences publicly available, which suggests that they were not.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 13,029 people with diagnosed HIV are included in the InfCareHIV cohort.

Rationale: The paper explicitly mentions the number of individuals included in the cohort, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 13,029

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the InfCareHIV cohort includes data from Sweden.

Rationale: The paper explicitly mentions Sweden as the country where the data were collected, which suggests that this is the country of origin for the sequenced samples.

Answer: Sweden

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the InfCareHIV cohort was established in 2003 and that data were collected up to 2022.

Rationale: The paper provides a time range for when the data were collected, which suggests that this is the time period during which the sequenced samples were obtained.

Answer: 2003-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any information about cloning, which suggests that it is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""viral sequences"" but does not specify which genes were sequenced.

Rationale: The paper does not provide enough information to determine which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" as sample types.

Rationale: The paper explicitly mentions plasma and PBMC as sample types, which suggests that these are the types of samples that were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment failure"" in the context of patient samples.

Rationale: The paper explicitly mentions virological failure and treatment failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" individuals.

Rationale: The paper explicitly mentions ART-experienced and treatment-experienced individuals, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" as drug classes.

Rationale: The paper explicitly mentions these drug classes, which suggests that individuals in the study received these classes of drugs before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", and ""lenacapavir"".

Rationale: The paper explicitly mentions these drugs, which suggests that individuals in the study received these drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",90
36961945,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making sequences publicly available, which suggests that it did not make sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that it did not report such numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""190 individuals were included"" in the study.

Rationale: The paper explicitly states that 190 individuals were included in the study, which indicates that samples were obtained from 190 individuals.

Answer: 190

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which suggests that it did not report such information.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Samples were collected from January 2005 to February 2020"".

Rationale: The paper explicitly states that samples were collected from January 2005 to February 2020, which indicates that the sequenced samples were obtained from 2005 to 2020.

Answer: 2005-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning samples prior to sequencing, which suggests that it did not perform such a step.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed"".

Rationale: The paper explicitly states that genotypic resistance testing was performed on PR, RT, and IN genes, which indicates that these genes were sequenced.

Answer: PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Next-generation sequencing (NGS) of HIV partial pol was performed"".

Rationale: The paper explicitly states that NGS was used for sequencing, which indicates that this method was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""genomic DNA was isolated from patient PBMCs"" and that ""viral RNA was extracted from plasma"".

Rationale: The paper explicitly states that both PBMCs and plasma were used as sample types, which indicates that both types were sequenced.

Answer: PBMCs, plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""no participants experienced virologic failure after initiating ART during the median 25.39 ± 3.13 months of follow-up on treatment"".

Rationale: The paper explicitly states that no participants experienced virologic failure, which suggests that sequences were not obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that it did not involve a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""participants were ART-naïve"" and that ""no participants had received ARV drugs prior to the study"".

Rationale: The paper explicitly states that participants were ART-naïve, which suggests that they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals in the study, which suggests that it did not report such information.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about specific drugs received by individuals in the study, which suggests that it did not report such information.

Answer: Not reported",91
36967989,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""protease inhibitors"" but does not explicitly state that genetic sequencing was performed on clinical samples from patients.

Rationale: The paper does not provide clear evidence that HIV sequences were obtained from patient samples. Although it mentions genotypic resistance testing and HIV sequencing, it does not specify that these were performed on clinical samples from patients.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic susceptibility"", ""drug susceptibility assay"", and ""IC50"" values, indicating that in vitro drug susceptibility data were reported.

Rationale: The paper provides evidence of in vitro drug susceptibility data, including phenotypic susceptibility assays and IC50 values.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide evidence that sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not applicable, as the paper does not mention GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide evidence that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""protease inhibitors"" and ""protease gene"", indicating that the protease gene was sequenced.

Rationale: The paper provides evidence that the protease gene was sequenced.

Answer: PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virologic failure"" and ""treatment failure"", indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper provides evidence that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide evidence that the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""treatment-experienced"" and ""prior ARV exposure"", indicating that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper provides evidence that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""protease inhibitors"" and ""NRTIs"", indicating that these drug classes were received by individuals in the study.

Rationale: The paper provides evidence that protease inhibitors and NRTIs were received by individuals in the study.

Answer: PI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""atazanavir"", ""darunavir"", ""fosamprenavir"", ""indinavir"", ""lopinavir"", ""nelfinavir"", ""saquinavir"", and ""tipranavir"", indicating that these drugs were received by individuals in the study.

Rationale: The paper provides evidence that these drugs were received by individuals in the study.

Answer: ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV
""""""",77
36982978,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""reverse transcriptase inhibitors"" which suggests that genetic sequencing was performed on clinical samples from patients. Additionally, the paper states ""HIV-2 RT is a heterodimer composed of two subunits, p68 and p54"" which implies that the sequencing was done on patient-derived samples.

Rationale: The paper provides evidence of genetic sequencing being performed on clinical samples from patients, which is a strong indication that HIV sequences from patient samples are reported in the paper.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""IC50"", and ""EC50"" which are values that are typically reported in in vitro drug susceptibility assays. Additionally, the paper states ""The assays use named platforms like PhenoSense, Monogram, Antivirogram, or Virco"" which suggests that in vitro drug susceptibility data is reported.

Rationale: The paper provides evidence of in vitro drug susceptibility data being reported, including values such as IC50 and EC50, and mentions specific platforms used for these assays.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database. Additionally, no accession numbers are provided in the paper.

Rationale: The paper does not provide any evidence that sequences were made publicly available, and no accession numbers are provided.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, so it is not possible to answer this question.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years during which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""reverse transcriptase"", ""protease"", and ""integrase"" which suggests that these genes were sequenced.

Rationale: The paper provides evidence that the reverse transcriptase, protease, and integrase genes were sequenced.

Answer: RT, PR, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" which suggests that these types of samples were sequenced.

Rationale: The paper provides evidence that plasma and PBMC samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment-experienced"" which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper provides evidence that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" and ""ARV drugs"" which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper provides evidence that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" which suggests that these drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper provides evidence that NRTI, NNRTI, PI, and INSTI drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""ABC"", ""EFV"", ""LPV/r"", ""DRV/r"", ""RAL"", and ""DTG"" which suggests that these drugs were received by individuals in the study before sample sequencing.

Rationale: The paper provides evidence that specific drugs such as 3TC, FTC, AZT, TDF, ABC, EFV, LPV/r, DRV/r, RAL, and DTG were received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, ABC, EFV, LPV/r, DRV/r, RAL, DTG",95
37017009,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and that the sequencing was done on the pol region encompassing protease and reverse transcriptase.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, but rather focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not report in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 899 participants had samples obtained for HIV sequencing.

Rationale: The paper explicitly states the number of participants who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 899

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from South Africa.

Rationale: The paper explicitly states the country of origin for the samples, which meets the criteria for a geographical answer.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between March 2017 and March 2019.

Rationale: The paper explicitly states the time period during which the samples were collected, which meets the criteria for a temporal answer.

Answer: 2017-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper explicitly states the region of the HIV genome that was sequenced, which meets the criteria for a specific answer.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that next-generation sequencing (NGS) was used.

Rationale: The paper explicitly states the sequencing method used, which meets the criteria for a specific answer.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that whole blood was collected and plasma was used for sequencing.

Rationale: The paper explicitly states the type of sample used for sequencing, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the participants had virological failure on a treatment regimen.

Rationale: The paper explicitly states that the participants had virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the participants had previously received ARV drugs.

Rationale: The paper explicitly states that the participants had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states the drug classes received by the participants, which meets the criteria for a specific answer.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants received specific ARV drugs, including abacavir, lamivudine, and efavirenz.

Rationale: The paper explicitly states the specific ARV drugs received by the participants, which meets the criteria for a specific answer.

Answer: Abacavir, lamivudine, efavirenz",78
37029656,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1223 ART-naive PLWH were evaluated.

Rationale: The paper explicitly states that 1223 ART-naive PLWH were evaluated, which indicates that 1223 individuals had samples obtained for HIV sequencing.

Answer: 1223

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples, which suggests that this information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted over the period 2009-2019.

Rationale: The paper explicitly states that the study was conducted over the period 2009-2019, which indicates that the sequenced samples were obtained during this time period.

Answer: 2009-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"", which indicates that the pol gene, including the integrase region, was sequenced.

Answer: Pol, including integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI PRISM 3130xl Genetic Analyzer"".

Rationale: The paper explicitly mentions ""Sanger sequencing"" and ""ABI PRISM 3130xl Genetic Analyzer"", which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""viral RNA was extracted from plasma"".

Rationale: The paper explicitly mentions ""plasma"" and ""viral RNA was extracted from plasma"", which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ART-naive PLWH, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included ART-naive PLWH, which indicates that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ART-naive PLWH, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that the study included ART-naive PLWH, which indicates that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drug classes, which suggests that this information is not available.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about specific drugs, which suggests that this information is not available.

Answer: Not reported",86
37039023,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and that the sequences were obtained from archived proviruses of patients with prolonged undetectable viral load.

Rationale: The paper explicitly states that the sequences were obtained from patient samples, and that the sequencing was performed on archived proviruses. This indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, and instead focuses on the analysis of archived proviruses from patients with prolonged undetectable viral load.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, and instead focuses on the analysis of archived proviruses. This suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.

Rationale: The paper explicitly states that the sequences were made publicly available through the Sequence Read Archive. This indicates that the sequences from the paper were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates. However, it does mention that the raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 86 HIV-positive patients were recruited for the study.

Rationale: The paper explicitly states that 86 HIV-positive patients were recruited for the study. This indicates that 86 individuals had samples obtained for HIV sequencing.

Answer: 86

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from patients in Rio de Janeiro (RJ) and Rio Grande do Sul (RS) in Brazil.

Rationale: The paper explicitly states that the samples were obtained from patients in RJ and RS in Brazil. This indicates that the sequenced samples were obtained from Brazil.

Answer: Brazil

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples from RJ were collected between February 2016 and November 2018, and the samples from RS were collected between August and December 2017.

Rationale: The paper explicitly states the years during which the samples were collected. This indicates that the sequenced samples were obtained from 2016 to 2018.

Answer: 2016-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on cloning prior to sequencing. This suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the near full-length genome (NFLG) of HIV was sequenced, which includes the protease, reverse transcriptase, integrase, and envelope genes.

Rationale: The paper explicitly states that the NFLG of HIV was sequenced, which includes multiple genes. This indicates that the protease, reverse transcriptase, integrase, and envelope genes were reported to have been sequenced.

Answer: Protease, reverse transcriptase, integrase, and envelope

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the Illumina MiSeq platform was used for sequencing.

Rationale: The paper explicitly states that the Illumina MiSeq platform was used for sequencing. This indicates that next-generation sequencing (NGS) was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that archived proviruses from peripheral blood mononuclear cells (PBMCs) were sequenced.

Rationale: The paper explicitly states that archived proviruses from PBMCs were sequenced. This indicates that PBMCs were the type of samples sequenced.

Answer: PBMCs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that all patients were in therapeutic success at the time of their inclusion in the study.

Rationale: The paper explicitly states that all patients were in therapeutic success, which suggests that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial. This suggests that the patients in the study were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patients were on antiretroviral therapy (ART) and had received ARV drugs.

Rationale: The paper explicitly states that the patients were on ART and had received ARV drugs. This indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states that the patients received NRTIs, NNRTIs, and PIs. This indicates that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients received specific ARV drugs such as 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, and darunavir.

Rationale: The paper explicitly states that the patients received specific ARV drugs. This indicates that these drugs were received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, and darunavir",98
37042390,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from patients, and that ""HIV RNA was extracted from plasma"" for sequencing.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that sequences were made publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019"".

Rationale: The paper explicitly mentions the number of patients who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 87

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in India.

Rationale: The paper explicitly mentions the country where the study was conducted, which meets the criteria for a geographical answer.

Answer: India

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between July 2016 and December 2019.

Rationale: The paper explicitly mentions the years when the study was conducted, which meets the criteria for a temporal answer.

Answer: 2016-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any evidence that samples were cloned prior to sequencing, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on the ""integrase, reverse transcriptase and protease genes"".

Rationale: The paper explicitly mentions the HIV genes that were sequenced, which meets the criteria for a specific answer.

Answer: Integrase, Reverse Transcriptase, Protease

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sequencing was done by a third-party commercial organization (Medauxin) using an Applied Biosystem 3730xl DNA Analyzer"".

Rationale: The paper explicitly mentions the sequencing method used, which meets the criteria for a specific answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""HIV RNA was extracted from plasma"" for sequencing.

Rationale: The paper explicitly mentions the type of sample that was sequenced, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""Thirteen out of 85 patients (15%) died during third-line therapy"" and that ""Five out of 13 patients who had virological failure at 12 months showed VL suppression at the end of the study"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any evidence that the patients were in a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019"" and that ""Patients were virally suppressed on long-term ART"".

Rationale: The paper explicitly mentions that the patients had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Patients received drugs belonging to a specific ARV class such as NRTI, PI, INSTI"" and that ""Patients were virally suppressed on long-term ART"".

Rationale: The paper explicitly mentions the drug classes that were received by the individuals in the study before sample sequencing, which meets the criteria for a specific answer.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Patients received drugs such as raltegravir, darunavir, ritonavir, and tenofovir"" and that ""Patients were virally suppressed on long-term ART"".

Rationale: The paper explicitly mentions the drugs that were received by the individuals in the study before sample sequencing, which meets the criteria for a specific answer.

Answer: Raltegravir, Darunavir, Ritonavir, Tenofovir",92
37052343,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 4310 eligible participants were included in the study.

Rationale: The paper explicitly mentions the number of participants included in the study, which indicates that 4310 individuals had samples obtained for HIV sequencing.

Answer: 4310

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Europe and Australia.

Rationale: The paper explicitly mentions the regions where the study was conducted, which suggests that the sequenced samples were obtained from Europe and Australia.

Answer: Europe, Australia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between 2014 and 2020.

Rationale: The paper explicitly mentions the years when the study was conducted, which suggests that the sequenced samples were obtained between 2014 and 2020.

Answer: 2014-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""pol genotyping/sequencing"" was performed.

Rationale: The paper explicitly mentions that ""pol genotyping/sequencing"" was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""plasma HIV-1 RNA"" was used for sequencing.

Rationale: The paper explicitly mentions that ""plasma HIV-1 RNA"" was used for sequencing, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some participants experienced virological failure.

Rationale: The paper explicitly mentions that some participants experienced virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some participants were ART-experienced.

Rationale: The paper explicitly mentions that some participants were ART-experienced, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions the different drug classes received by participants, which suggests that NRTIs, NNRTIs, PIs, and INSTIs were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as abacavir, lamivudine, tenofovir, emtricitabine, efavirenz, rilpivirine, darunavir, and dolutegravir.

Rationale: The paper explicitly mentions specific drugs received by participants, which suggests that these drugs were received by individuals in the study before sample sequencing.

Answer: Abacavir, lamivudine, tenofovir, emtricitabine, efavirenz, rilpivirine, darunavir, dolutegravir",88
37071019,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"" were performed on clinical samples from patients.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic susceptibility"", ""drug susceptibility assay"", and ""IC50"" values, and uses cell-based susceptibility assays.

Rationale: The paper reports in vitro drug susceptibility data, including IC50 values and cell-based susceptibility assays, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: The paper does not provide any information about making the sequences publicly available, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years during which the sequenced samples were obtained, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""integrase coding region of pol"" and ""IN"" sequencing.

Rationale: The paper explicitly states that the integrase coding region of pol was sequenced, which meets the criteria for an ""IN"" answer.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"".

Rationale: The paper explicitly states that Sanger sequencing was used, which meets the criteria for a ""Sanger sequencing"" answer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"" in the context of sequencing.

Rationale: The paper explicitly states that sequencing was performed on individuals with virological failure on a treatment regimen, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" individuals.

Rationale: The paper explicitly states that sequencing was performed on individuals who had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""INSTI"" and ""DTG"" in the context of sequencing.

Rationale: The paper explicitly states that individuals received INSTI drugs, including DTG, before sample sequencing, which meets the criteria for an ""INSTI"" answer.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""DTG"" and ""BIC"" in the context of sequencing.

Rationale: The paper explicitly states that individuals received DTG and BIC before sample sequencing, which meets the criteria for a ""DTG, BIC"" answer.

Answer: DTG, BIC
""""""",84
37085698,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences have been deposited in the GenBank repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that sequences have been deposited in the GenBank repository, which indicates that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences have been deposited in the GenBank repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that sequences have been deposited in the GenBank repository with accession numbers from MW560010 to MW560058.

Answer: MW560010 to MW560058

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 49 study participants had samples obtained for HIV sequencing.

Rationale: The paper explicitly states that 49 study participants had samples obtained for HIV sequencing.

Answer: 49

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin of the samples.

Rationale: Although the paper does not explicitly mention the country of origin of the samples, it can be inferred that the samples were obtained from Ethiopia, as the paper mentions that the study was conducted in Addis Ababa, Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between June and December 2018.

Rationale: The paper explicitly states that the study was conducted between June and December 2018, which indicates that the samples were obtained during this time period.

Answer: 2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning or any cloning-related techniques, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the IN region of the HIV genome was sequenced.

Rationale: The paper explicitly states that the IN region of the HIV genome was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that all study participants were ART-naive.

Rationale: The paper explicitly states that all study participants were ART-naive, which indicates that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that all study participants were ART-naive.

Rationale: The paper explicitly states that all study participants were ART-naive, which indicates that no HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that all study participants were ART-naive.

Rationale: The paper explicitly states that all study participants were ART-naive, which indicates that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that all study participants were ART-naive.

Rationale: The paper explicitly states that all study participants were ART-naive, which indicates that no drugs were received by individuals in the study before sample sequencing.

Answer: None",91
37104815,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 121 participants were enrolled in the substudy.

Rationale: The paper explicitly mentions the number of participants enrolled in the substudy, which indicates the number of individuals who had samples obtained for HIV sequencing.

Answer: 121

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples, which suggests that it was not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between 2017 and 2019.

Rationale: The paper explicitly mentions the years during which the study was conducted, which indicates the years during which the sequenced samples were obtained.

Answer: 2017-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the HIV-1 genome was sequenced, including the reverse transcriptase (RT), protease (PR), and integrase (INT) regions.

Rationale: The paper explicitly mentions the HIV genes that were sequenced, which indicates that the RT, PR, and INT regions were sequenced.

Answer: RT, PR, INT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Illumina technology was used for sequencing.

Rationale: The paper explicitly mentions the sequencing method used, which indicates that Illumina technology was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma and PBMC samples were sequenced.

Rationale: The paper explicitly mentions the types of samples that were sequenced, which indicates that plasma and PBMC samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some participants experienced virological failure.

Rationale: The paper explicitly mentions that some participants experienced virological failure, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a clinical trial.

Rationale: The paper explicitly mentions that the study was a clinical trial, which indicates that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some participants were ART-experienced.

Rationale: The paper explicitly mentions that some participants were ART-experienced, which indicates that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions the drug classes that were received by some participants, which indicates that NRTIs, NNRTIs, PIs, and INSTIs were received.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received specific drugs such as tenofovir, emtricitabine, and rilpivirine.

Rationale: The paper explicitly mentions the specific drugs that were received by some participants, which indicates that tenofovir, emtricitabine, and rilpivirine were received.

Answer: Tenofovir, emtricitabine, rilpivirine",94
37112971,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not provide accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""4481 treatment-naïve HIV-infected patients"" had samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 4481

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from ""Russia"".

Rationale: The paper explicitly mentions the country from which the samples were obtained.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were obtained between ""2006"" and ""2022"".

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2006-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that it is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the ""pol gene regions encoding the PR-RT"" and ""INT"" were sequenced.

Rationale: The paper explicitly mentions the HIV genes that were sequenced.

Answer: Pol, INT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger-based or NGS-based"" sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger-based or NGS-based

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that ""plasma"" and ""PBMC"" samples were sequenced.

Rationale: The paper explicitly mentions the types of samples that were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included ""treatment-naïve"" individuals, which suggests that they did not have virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the individuals were treatment-naïve, which suggests that they did not have virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that it is not reported.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included ""treatment-naïve"" individuals, which suggests that they did not have previously received ARV drugs.

Rationale: The paper explicitly mentions that the individuals were treatment-naïve, which suggests that they did not have previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals before sample sequencing, which suggests that it is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information about specific drugs received by individuals before sample sequencing, which suggests that it is not reported.

Answer: Not reported",92
37147875,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from a patient, and the sequencing was done on the reverse transcriptase, protease, and integrase genes.

Rationale: The paper explicitly mentions that genetic sequencing was performed on a patient sample, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, but it does mention the use of next-generation sequencing (NGS) to detect resistance-associated mutations.

Rationale: The paper does not provide in vitro drug susceptibility data, but it does provide information on the use of NGS to detect resistance-associated mutations, which is not the same as in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information on whether the sequences were made publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that the sequencing was performed on a single patient.

Rationale: The paper explicitly mentions that the sequencing was performed on a single patient, which meets the criteria for a ""1"" answer.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the patient was from France.

Rationale: The paper explicitly mentions that the patient was from France, which meets the criteria for a ""France"" answer.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient was diagnosed in 2022.

Rationale: The paper explicitly mentions that the patient was diagnosed in 2022, which meets the criteria for a ""2022"" answer.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on whether the samples were cloned prior to sequencing, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the reverse transcriptase, protease, and integrase genes.

Rationale: The paper explicitly mentions that the sequencing was done on the reverse transcriptase, protease, and integrase genes, which meets the criteria for a ""RT, PR, IN"" answer.

Answer: RT, PR, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that next-generation sequencing (NGS) was used to detect resistance-associated mutations.

Rationale: The paper explicitly mentions that NGS was used to detect resistance-associated mutations, which meets the criteria for a ""NGS"" answer.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequencing was done on plasma samples.

Rationale: The paper explicitly mentions that the sequencing was done on plasma samples, which meets the criteria for a ""Plasma"" answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient was not on treatment at the time of sequencing.

Rationale: The paper explicitly mentions that the patient was not on treatment at the time of sequencing, which meets the criteria for a ""No"" answer.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patient was in a clinical trial.

Rationale: The paper does not provide any information on whether the patient was in a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was not on treatment at the time of sequencing.

Rationale: The paper explicitly mentions that the patient was not on treatment at the time of sequencing, which meets the criteria for a ""No"" answer.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was not on treatment at the time of sequencing.

Rationale: The paper explicitly mentions that the patient was not on treatment at the time of sequencing, which meets the criteria for a ""None"" answer.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was not on treatment at the time of sequencing.

Rationale: The paper explicitly mentions that the patient was not on treatment at the time of sequencing, which meets the criteria for a ""None"" answer.

Answer: None",87
37272233,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about making sequences publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 248 patients were analyzed.

Rationale: The paper explicitly states that 248 patients were analyzed, which meets the criteria for a ""Yes"" answer.

Answer: 248

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information about the country of origin for the samples, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study period was from 2012 to 2020.

Rationale: The paper explicitly states that the study period was from 2012 to 2020, which meets the criteria for a ""Yes"" answer.

Answer: 2012-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related methods.

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly states that pol genotyping/sequencing and integrase coding region of pol were performed, which meets the criteria for a ""Yes"" answer.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""ABI 3500xL Dx genetic analyzer"" and ""Sanger sequencing"".

Rationale: The paper explicitly states that Sanger sequencing was used, which meets the criteria for a ""Yes"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"".

Rationale: The paper explicitly states that plasma and PBMC were used, which meets the criteria for a ""Yes"" answer.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly states that virologic failure and failing therapy were considered, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper explicitly states that ART-experienced and treatment-experienced individuals were considered, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly states that NRTI, NNRTI, PI, and INSTI were considered, which meets the criteria for a ""Yes"" answer.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""zidovudine"", ""lamivudine"", ""efavirenz"", and ""raltegravir"".

Rationale: The paper explicitly states that specific drugs were considered, which meets the criteria for a ""Yes"" answer.

Answer: zidovudine, lamivudine, efavirenz, raltegravir",92
37279764,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously."" and ""All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255).""

Rationale: The paper mentions that sequencing was performed on clinical samples, and the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing, phylogenetics, and epidemiology, but does not report in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""GenBank accession no. MW947591–MW957968, OP058117–OP058658"" were used for the sequences.

Rationale: The paper provides GenBank accession numbers for the sequences, indicating that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that ""GenBank accession no. MW947591–MW957968, OP058117–OP058658"" were used for the sequences.

Rationale: The paper provides the GenBank accession numbers for the sequences.

Answer: MW947591–MW957968, OP058117–OP058658

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 12,320 participants with demographic data and partial pol sequences were included in this study.""

Rationale: The paper reports the total number of participants who had samples obtained for HIV sequencing.

Answer: 12,320

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the samples.

Rationale: Although the paper does not explicitly mention the country of origin, it can be inferred that the samples were obtained from China, as the paper mentions ""Shenzhen, China"" in the abstract.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Clinical samples were collected between January 2011 and December 2019.""

Rationale: The paper reports the years during which the clinical samples were collected.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255).""

Rationale: The paper reports that the partial pol gene region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: Although the paper does not explicitly mention the sequencing method, it can be inferred that Sanger sequencing was used, as the paper mentions ""PCR amplification work-up and sequencing were performed essentially as described previously.""

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not explicitly mention the type of samples sequenced.

Rationale: Although the paper does not explicitly mention the type of samples sequenced, it can be inferred that plasma samples were used, as the paper mentions ""viral RNA was extracted from plasma.""

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""The prevalence of TDR was increased in populations with the characteristics of CRF07_BC, being single, educated to junior college level and above, MSM and male.""

Rationale: The paper reports that the prevalence of TDR was increased in certain populations, but does not explicitly mention virological failure on a treatment regimen.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""The patients with TDRMs diagnosed in 2017–19 were younger than those in 2011–16.""

Rationale: The paper reports that the patients with TDRMs were diagnosed in different years, but does not explicitly mention previous ARV drug use.

Answer: Not Reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not Reported",82
37327289,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly states that sequences were submitted to public databases and provides accession numbers, which indicates that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that the sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].

Rationale: The paper provides a range of accession numbers, which can be used to retrieve the sequences from the database.

Answer: LC723952-LC724015
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 64 HIV-seropositive plasma samples were collected from FSWs.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 64
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, Kenya.

Rationale: The paper explicitly states the country where the samples were obtained.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the participants were recruited between November 2020 and April 2021.

Rationale: The paper explicitly states the time period when the samples were obtained.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the *pol* gene was amplified and genotyped using Sanger sequencing.

Rationale: The paper explicitly states the gene that was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly states the type of sample used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the participants were treatment-naive.

Rationale: The paper explicitly states that the participants were treatment-naive, which suggests that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the participants were treatment-naive.

Rationale: The paper explicitly states that the participants were treatment-naive, which suggests that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes.

Rationale: The paper does not provide any information about drug classes, which suggests that no drug classes were received by individuals in the study before sample sequencing.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs.

Rationale: The paper does not provide any information about drugs, which suggests that no drugs were received by individuals in the study before sample sequencing.

Answer: None
""""""",81
37340869,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, and it focuses on sequencing and phylogenetics.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about the GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1651 participants were included in the study.

Rationale: The paper explicitly mentions the number of participants included in the study.

Answer: 1651

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in multiple countries, but it does not provide a list of specific countries.

Rationale: The paper does not provide enough information to determine the specific countries where the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted over a period of several years, but it does not provide specific dates.

Rationale: The paper does not provide enough information to determine the specific years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study focused on the pol gene.

Rationale: The paper explicitly mentions the pol gene, which suggests that it was the primary focus of the study.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide enough information to determine the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used.

Rationale: The paper explicitly mentions plasma samples, which suggests that they were the primary source of sequencing material.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some participants experienced virological failure.

Rationale: The paper explicitly mentions virological failure, which suggests that some sequences were obtained from individuals who experienced treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a clinical trial.

Rationale: The paper explicitly mentions that the study was a clinical trial, which suggests that the patients were part of a trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some participants were treatment-experienced.

Rationale: The paper explicitly mentions treatment-experienced participants, which suggests that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received INSTIs and NNRTIs.

Rationale: The paper explicitly mentions INSTIs and NNRTIs, which suggests that these drug classes were received by some participants before sample sequencing.

Answer: INSTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received cabotegravir and rilpivirine.

Rationale: The paper explicitly mentions cabotegravir and rilpivirine, which suggests that these drugs were received by some participants before sample sequencing.

Answer: Cabotegravir, rilpivirine",77
37358226,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from patients, and that ""viral load outcomes"" were reported.

Rationale: The paper mentions ""genotypic resistance testing"" and ""viral load outcomes"", which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""in vitro drug susceptibility data"" or any related terms.

Rationale: The paper does not provide any information about in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention ""GenBank accession numbers"" or any other public sequence databases.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART"".

Rationale: The paper mentions the number of adults who transitioned to dolutegravir-based ART, which suggests that samples were obtained from these individuals.

Answer: 14,242

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Lesotho.

Rationale: The paper mentions the country where the study was conducted, which suggests that the samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention specific years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention ""cloning"" or any related terms.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention specific sequencing methods.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""viral load"" outcomes.

Rationale: The paper mentions ""plasma"" and ""viral load"" outcomes, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic failure"" was one of the outcomes reported.

Rationale: The paper mentions ""virologic failure"", which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention ""clinical trial"" or any related terms.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""14,242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART"".

Rationale: The paper mentions that the adults had previously received ARV drugs (efavirenz or nevirapine) before transitioning to dolutegravir-based ART.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""efavirenz"" and ""nevirapine"", which are NNRTIs, and ""dolutegravir"", which is an INSTI.

Rationale: The paper mentions specific drug classes (NNRTIs and INSTIs) that were received by the individuals before sample sequencing.

Answer: NNRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""efavirenz"", ""nevirapine"", and ""dolutegravir"".

Rationale: The paper mentions specific drugs that were received by the individuals before sample sequencing.

Answer: Efavirenz, nevirapine, dolutegravir",76
37376649,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations."" and ""Participants' baseline whole blood samples were used for the GenoSure Archive assay.""

Rationale: The paper mentions that HIV-1 proviral DNA genotyping was conducted using next-generation sequencing (NGS) on whole blood samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.""

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it does provide a link to request anonymized individual participant data and study documents.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 734 participants were randomized and 741 received at least one dose of the study treatments (exposed population). Of those treated, 464 (63%) participants had historical genotypes with 221/369 (60%) in the DTG/3TC and 243/372 (65%) in the TBR group.""

Rationale: The paper reports that 734 participants were randomized, but it does not explicitly state how many individuals had samples obtained for HIV sequencing. However, it does provide information on the number of participants with historical genotypes.

Answer: Not Reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""The GenoSure Archive assay failed to provide a result for 80 of the 734 (11%) samples tested.""

Rationale: The paper does not explicitly state whether samples were cloned prior to sequencing. However, it does mention that the GenoSure Archive assay failed to provide a result for some samples, which may indicate that cloning was not performed.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.""

Rationale: The paper mentions that the HIV-1 polymerase region was analyzed using next-generation sequencing (NGS), which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.""

Rationale: The paper mentions that next-generation sequencing (NGS) was used to analyze the HIV-1 polymerase region.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""Participants' baseline whole blood samples were used for the GenoSure Archive assay.""

Rationale: The paper mentions that whole blood samples were used for sequencing.

Answer: Whole Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""No participants in the DTG/3TC group met protocol-defined CVW criteria through week 144, while three participants in the TBR group (all without any archived major RAMs) met CVW criteria with no resistance observed at virologic failure time.""

Rationale: The paper mentions that some participants met protocol-defined CVW criteria, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144.""

Rationale: The paper mentions that the study was registered on ClinicalTrials.gov and had an NCT number, which indicates that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""Participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results, if available.""

Rationale: The paper mentions that participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs, which indicates that some participants may have previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results, if available.""

Rationale: The paper mentions that participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs, which indicates that some participants may have previously received NRTI or INSTI drugs.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results, if available.""

Rationale: The paper mentions that participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs, which indicates that some participants may have previously received specific NRTI or INSTI drugs.

Answer: Not Reported",111
37381002,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Pol gene of HIV-1 viruses in blood samples of EDTA anticoagulants from 398 patients with failed antiviral treatment was successfully amplified by using an in-house assay."" and ""Viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland).""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, specifically mentioning the use of blood samples and plasma.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing, phylogenetics, and epidemiology, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about depositing sequences in public databases or making them available for download.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers or provide any information about depositing sequences in public databases.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 398 viral pol gene sequences were successfully sequenced.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 398

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Suzhou City, China.

Rationale: The paper explicitly states the location where the samples were collected.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2017 to 2020.

Rationale: The paper explicitly states the time period during which the samples were collected.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning or using cloning kits.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the partial *pol* gene fragment of HIV-1 virus was amplified by using in-house polymerase chain reaction (PCR) method.""

Rationale: The paper explicitly states that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sanger sequencing method"" was used.

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""blood plasma"" was used for sequencing.

Rationale: The paper explicitly states the type of samples used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ""people living with HIV who have received antiviral therapy for more than 1 year were confirmed to be ineffective (viral load ≥1000 copies/ml)"".

Rationale: The paper explicitly states that the individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial or mention any trial-related terms.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the individuals had received antiviral therapy for more than 1 year.

Rationale: The paper explicitly states that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about the specific drug classes received by the individuals.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about the specific drugs received by the individuals.

Answer: Not reported",73
37439411,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: We retrieved HIV-1 RNA protease/reverse transcriptase sequences, demographic and clinical data of adult PLWH from the Antiviral Response Cohort Analysis (ARCA) database. Transmitted drug resistance (TDR) was found in 12.5% and declined from 17.3% in 2000--2003 to 10.9% in 2016--2020 ( *p* = 0.003). Predictors of TDR were viral subtype B \[vs. non-B, adjusted odds ratio (aOR) = 1.94, *p* \< 0.001\], zenith viral load (VL) (per 1 log ~10~ higher, aOR = 0.86, *p* = 0.013), nadir CD4 count (per 100 cells/μL increase aOR = 0.95, *p* = 0.013).

Rationale: The paper reports HIV sequences from patient samples, including their corresponding GenBank accession numbers. The paper states that genetic sequencing was performed on clinical samples from patients, and it refers to genotypic resistance testing and HIV sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It only reports genotypic resistance and mutation prevalence.

Rationale: The paper does not report in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. It only focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not report that sequences were submitted to GenBank or any other public sequence database. It does not provide accession numbers for GenBank or any other database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: We included 5982 naïves and 28 505 genotypes from 9387 treatment-experienced PLWH.

Rationale: The paper reports that 5982 naïve individuals and 9387 treatment-experienced individuals had samples obtained for HIV sequencing.

Answer: 5982 naïve individuals and 9387 treatment-experienced individuals

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries where the samples were obtained. However, it mentions that the study was conducted in Italy.

Rationale: Although the paper does not explicitly mention the countries where the samples were obtained, it can be inferred that the samples were obtained from Italy, as the study was conducted in Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were obtained between 2000 and 2020.

Rationale: The paper reports that the samples were obtained between 2000 and 2020, as it mentions that the study analyzed data from 2000 to 2020.

Answer: 2000-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the protease and reverse transcriptase genes were sequenced.

Rationale: The paper mentions that the protease and reverse transcriptase genes were sequenced, as it reports on the genotypic resistance of these genes.

Answer: Protease and reverse transcriptase

**Question 10: What method was used for sequencing?**

Evidence: Not available.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were sequenced.

Rationale: The paper mentions that viral RNA was extracted from plasma, indicating that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: Yes, the paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequencing was performed on individuals with virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: No, the paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information that suggests the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: Yes, the paper reports that some individuals had previously received ARV drugs.

Rationale: The paper mentions that some individuals were treatment-experienced, indicating that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some individuals received NNRTIs, NRTIs, and PIs before sample sequencing.

Rationale: The paper mentions that some individuals were treatment-experienced and had received NNRTIs, NRTIs, and PIs before sample sequencing.

Answer: NNRTIs, NRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that some individuals received efavirenz, nevirapine, and rilpivirine before sample sequencing.

Rationale: The paper mentions that some individuals were treatment-experienced and had received efavirenz, nevirapine, and rilpivirine before sample sequencing.

Answer: Efavirenz, nevirapine, and rilpivirine",97
37495103,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, specifically on plasma samples. The paper also mentions that HIV-1 RNA was isolated from 250 µL of plasma and that reverse transcription and PCR were performed to amplify the HIV-1 PR-RT fragment.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer. Additionally, the paper provides details on the methods used to isolate and amplify the HIV-1 RNA from plasma samples, which further supports the answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related methods such as phenotypic susceptibility testing, IC50 values, or cell-based susceptibility assays.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). There is also no mention of accession numbers or any other indication that the sequences were made publicly available.

Rationale: The paper does not provide any information on the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information on GenBank accession numbers, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study cohort included 271 patients who were on first-line ART and visited the Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper explicitly states the number of patients in the study cohort, which meets the criteria for a ""Yes"" answer.

Answer: 271

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in the Novosibirsk region of Russia.

Rationale: The paper explicitly states the location of the study, which meets the criteria for a ""Yes"" answer.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between March 2018 and August 2022.

Rationale: The paper explicitly states the time period during which the study was conducted, which meets the criteria for a ""Yes"" answer.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related methods such as TA cloning or Topo TA cloning.

Rationale: The paper does not provide any information on cloning, which meets the criteria for a ""No"" answer.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 PR-RT fragment was amplified and sequenced.

Rationale: The paper explicitly states the region of the HIV-1 genome that was sequenced, which meets the criteria for a ""Yes"" answer.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser.

Rationale: The paper explicitly states the sequencing method used, which meets the criteria for a ""Yes"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 RNA was isolated from 250 µL of plasma.

Rationale: The paper explicitly states the type of sample used for sequencing, which meets the criteria for a ""Yes"" answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients who experienced virological failure while on first-line ART.

Rationale: The paper explicitly states that the study included patients with virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related information such as randomization, intervention arms, or trial registration.

Rationale: The paper does not provide any information on a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who were on first-line ART and experienced virological failure.

Rationale: The paper explicitly states that the study included patients who had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients received first-line ART regimens that included NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states the drug classes used in the study, which meets the criteria for a ""Yes"" answer.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as TDF, 3TC, EFV, LPV/r, and DTG.

Rationale: The paper explicitly states the specific drugs used in the study, which meets the criteria for a ""Yes"" answer.

Answer: TDF, 3TC, EFV, LPV/r, DTG",92
37498738,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: Since the paper does not report accession numbers for GenBank or any of the above databases, it is not possible to extract the GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study"" were enrolled in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 101

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Switzerland, as indicated by the mention of the ""Zurich Primary HIV Infection Study and Swiss HIV Cohort Study"".

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the samples were obtained from Switzerland.

Answer: Switzerland

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not available.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that cloning was not performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""near full-length HIV-1 proviral polymerase chain reaction"" and ""next-generation sequencing"", which suggests that the entire HIV genome was sequenced.

Rationale: The paper explicitly mentions that near full-length HIV-1 proviral polymerase chain reaction was performed, which suggests that the entire HIV genome was sequenced.

Answer: Full length genome

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""next-generation sequencing (NGS)"" and ""Illumina platform"", which suggests that NGS was used for sequencing.

Rationale: The paper explicitly mentions that NGS was used for sequencing, which suggests that this was the method used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""peripheral blood mononuclear cells (PBMCs)"" and ""proviral DNA"", which suggests that PBMCs were sequenced.

Rationale: The paper explicitly mentions that PBMCs were sequenced, which suggests that this was the type of sample used.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention ""virologic or virological failure (VF)"" or ""failing therapy or regimen"".

Rationale: The paper does not provide any information about virological failure, which suggests that sequences were not obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a ""randomized clinical trial"" and that it was registered at ClinicalTrials.gov.

Rationale: The paper explicitly mentions that the study was a clinical trial, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were ""ART-experienced"" and that they had received ""dolutegravir monotherapy"" or ""combination antiretroviral therapy (cART)"".

Rationale: The paper explicitly mentions that the patients were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients received ""dolutegravir monotherapy"" or ""combination antiretroviral therapy (cART)"", which suggests that they received INSTI and NRTI drugs.

Rationale: The paper explicitly mentions that the patients received dolutegravir monotherapy or cART, which suggests that they received INSTI and NRTI drugs.

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients received ""dolutegravir monotherapy"" or ""combination antiretroviral therapy (cART)"", which suggests that they received dolutegravir and other ARV drugs.

Rationale: The paper explicitly mentions that the patients received dolutegravir monotherapy or cART, which suggests that they received dolutegravir and other ARV drugs.

Answer: Dolutegravir, other ARV drugs",100
37515095,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not provide accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan.

Rationale: The paper explicitly states that 968 sequences were collected, which indicates that 968 individuals had samples obtained for HIV sequencing.

Answer: 968

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected from all regions of Kazakhstan.

Rationale: The paper explicitly states that samples were collected from Kazakhstan, which indicates that the sequenced samples were obtained from Kazakhstan.

Answer: Kazakhstan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that samples were collected between 2017 and 2020.

Rationale: The paper explicitly states that samples were collected between 2017 and 2020, which indicates that the sequenced samples were obtained from these years.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequence data consisted of partial HIV-1 *pol* gene sequences (covering protease and the 5′-end of reverse transcriptase, positions 2253 to 3337 on the HXB2 reference genome).

Rationale: The paper explicitly states that the *pol* gene was sequenced, which includes the protease and reverse transcriptase genes.

Answer: Pol (PR, RT)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Applied Biosystems ^®^ Genetic Analyzer 3130"" and ""AmpliSens ^®^ HIV-Resist-Seq"".

Rationale: The paper explicitly states that the Applied Biosystems Genetic Analyzer 3130 was used, which is a Sanger sequencing platform.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""blood samples"" and ""plasma"".

Rationale: The paper explicitly states that blood samples and plasma were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that 311 sequences exhibited high-level drug resistance, and that the odds of high-level drug resistance were higher for individuals on second- and mixed-generation regimens.

Rationale: The paper explicitly states that high-level drug resistance was observed, which suggests that some individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: Not available.

Rationale: The paper does not provide any information about clinical trials.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that 464 individuals were on second-generation ART regimens, and that 291 individuals were on mixed-generation regimens.

Rationale: The paper explicitly states that some individuals were on ART regimens, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that 464 individuals were on second-generation ART regimens, which included NRTIs and NNRTIs.

Rationale: The paper explicitly states that second-generation ART regimens were used, which includes NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the combination of FTC + TDF + EFV was the most common ART regimen administered.

Rationale: The paper explicitly states that FTC, TDF, and EFV were used in the most common ART regimen.

Answer: FTC, TDF, EFV",90
37515146,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing was carried out in the pol gene (reverse transcriptase and protease regions)"" and that ""viral RNA was extracted from plasma"" for sequencing.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, specifically on plasma samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, but rather focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not report any in vitro susceptibility data, but rather focuses on genotypic resistance testing and sequencing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.""

Rationale: The paper explicitly mentions that the sequences have been deposited in GenBank and provides the accession numbers.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.""

Rationale: The paper provides the accession numbers for the sequences deposited in GenBank.

Answer: MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples.""

Rationale: The paper explicitly mentions the number of participants who had samples obtained for HIV sequencing.

Answer: 379

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Cameroon.

Rationale: The paper explicitly mentions the country where the study was conducted.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2014 to 2019.

Rationale: The paper explicitly mentions the years during which the study was conducted.

Answer: 2014-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""genotypic resistance testing was carried out in the pol gene (reverse transcriptase and protease regions)"".

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: Pol (reverse transcriptase and protease regions)

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""genotypic resistance testing was carried out using a previously validated in-house genotyping assay"" and that ""the products of the sequencing reaction obtained were purified by exclusion chromatography on SEPHADEX G50 resin and then sequenced using a genetic analyzer (ABI 3500)"".

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" for sequencing.

Rationale: The paper explicitly mentions the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ""ART-naive patients"" and that ""samples were collected at baseline"".

Rationale: The paper explicitly mentions that the study included ART-naive patients and that samples were collected at baseline, indicating that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ""ART-naive patients"" and that ""samples were collected at baseline"".

Rationale: The paper explicitly mentions that the study included ART-naive patients and that samples were collected at baseline, indicating that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals in the study before sample sequencing.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drugs received by individuals in the study before sample sequencing.

Answer: Not Reported",83
37520425,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and it provides accession numbers for GenBank.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which indicates that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the accession numbers are OQ627458-OQ627474.

Rationale: The paper provides a range of accession numbers, which can be used to retrieve the sequences from GenBank.

Answer: OQ627458-OQ627474

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 436 patients were in the DTG cohort and 466 patients were in the NNRTI cohort.

Rationale: The paper provides the number of patients in each cohort, which can be used to determine the total number of individuals who had samples obtained for HIV sequencing.

Answer: 902

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Tanzania.

Rationale: The paper explicitly states that the study was conducted in Tanzania, which indicates that the sequenced samples were obtained from Tanzania.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2016 and 2020.

Rationale: The paper provides a range of years, which can be used to determine the years during which the sequenced samples were obtained.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly states that the pol region was sequenced, which includes the protease and reverse transcriptase genes.

Answer: Pol (including protease and reverse transcriptase)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which is a widely used method for sequencing DNA.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which is a common type of sample used for HIV sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that some patients had virological failure on a treatment regimen.

Rationale: The paper explicitly states that some patients had virological failure on a treatment regimen, which indicates that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that some patients were treatment-experienced.

Rationale: The paper explicitly states that some patients were treatment-experienced, which indicates that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states that some patients received NRTIs, NNRTIs, and PIs, which are common classes of ARV drugs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received dolutegravir, efavirenz, and tenofovir.

Rationale: The paper explicitly states that some patients received dolutegravir, efavirenz, and tenofovir, which are specific ARV drugs.

Answer: Dolutegravir, efavirenz, tenofovir",89
37537871,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and the methods mention ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, but rather focuses on sequencing and phylogenetics.

Rationale: The paper does not report in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or other public databases.

Rationale: The paper does not provide any information about making sequences publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that a total of 77 plasma samples were obtained from patients.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 77

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected from patients in Hong Kong.

Rationale: The paper explicitly mentions the country where the samples were collected, which meets the criteria for a geographical answer.

Answer: Hong Kong

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected between 2002 and 2014.

Rationale: The paper explicitly mentions the year range when the samples were collected, which meets the criteria for a temporal answer.

Answer: 2002-2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the protease and reverse transcriptase genes were sequenced.

Rationale: The paper explicitly mentions the genes that were sequenced, which meets the criteria for a specific answer.

Answer: Protease and reverse transcriptase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Oxford Nanopore Technologies (ONT) sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used, which meets the criteria for a specific answer.

Answer: ONT sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were sequenced.

Rationale: The paper explicitly mentions the type of samples that were sequenced, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some patients had virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that some patients had virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some patients had previously received ARV drugs.

Rationale: The paper explicitly mentions that some patients had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs, which meets the criteria for a ""Not reported"" answer.

Answer: Not reported",80
37540331,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 RNA levels were quantified using polymerase chain reaction (PCR) assays with a detection limit of 47 copies/ml."" and ""Patients' routine laboratory tests were performed according to the clinic visit schedule every six months.""

Rationale: The paper mentions the use of PCR assays to quantify HIV-1 RNA levels, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report submitting sequences to GenBank or any other public sequence database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable.

Rationale: Since the paper does not report making sequences publicly available, there are no GenBank accession numbers to report.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 102 PLWHs were screened for eligibility, of which 17 persons did not meet the inclusion criteria. Finally, 85 patients were randomly assigned to receive TAF plus DTG regimen (n = 43) or to continue the previous 3DR (n = 42).""

Rationale: The paper reports that 85 patients were randomly assigned to receive either TAF plus DTG regimen or to continue the previous 3DR.

Answer: 85

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not report the country of origin for the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years during which the samples were obtained.

Rationale: The paper does not report the years during which the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report using cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not report specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of PCR assays.

Rationale: The paper reports using PCR assays to quantify HIV-1 RNA levels, but does not specify the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions the use of plasma samples.

Rationale: The paper reports using plasma samples for HIV-1 RNA quantification.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not report any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""This study was registered at the Iranian Registry of Clinical Trials (IRCT20191005044984N1, registered at 2019--12-21) and conducted as an open-label randomized non-inferiority trial.""

Rationale: The paper reports that the study was registered at the Iranian Registry of Clinical Trials and conducted as an open-label randomized non-inferiority trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that patients were treatment-experienced.

Rationale: The paper reports that patients were treatment-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of TAF and DTG.

Rationale: The paper reports using TAF and DTG, which are NRTI and INSTI drugs, respectively.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of TAF and DTG.

Rationale: The paper reports using TAF and DTG.

Answer: TAF, DTG",78
37541705,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 57 participants were enrolled and initiated study drug.

Rationale: The paper explicitly mentions the number of participants who had samples obtained for HIV sequencing.

Answer: 57

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper explicitly mentions the countries where the study sites were located, which suggests that the sequenced samples were obtained from these countries.

Answer: Botswana, South Africa, Thailand, U.S.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from September 9, 2020 through June 28, 2021.

Rationale: The paper explicitly mentions the enrollment period, which suggests that the sequenced samples were obtained during this time.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that this information is not available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not available.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not explicitly mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples, which suggests that this information is not available.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that all treatment-experienced participants maintained suppression for 24 weeks, but one treatment-naive participant did not achieve suppression.

Rationale: The paper suggests that some participants may have had virological failure, but it does not explicitly state that sequences were obtained from individuals with virological failure.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study is a phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly mentions that the study is a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that most participants were treatment-experienced at entry.

Rationale: The paper suggests that some participants had previously received ARV drugs, but it does not explicitly state that sequences were obtained from these individuals.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants received abacavir, dolutegravir, and lamivudine.

Rationale: The paper explicitly mentions the drug classes that were received by participants.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that participants received abacavir, dolutegravir, and lamivudine.

Rationale: The paper explicitly mentions the specific drugs that were received by participants.

Answer: Abacavir, dolutegravir, lamivudine",85
37546367,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and the methods mention ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping. The paper also reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper meets the criteria for reporting HIV sequences from patient samples, as it mentions genetic sequencing on clinical samples from patients and provides GenBank accession numbers.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results do not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not meet the criteria for reporting in vitro drug susceptibility data, as it does not mention the required terms or report the required values.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides accession numbers for GenBank. The paper also states that sequences have been deposited or made available in a sequence database.

Rationale: The paper meets the criteria for making sequences publicly available, as it reports submission to GenBank and provides accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports that the partial pol nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ886077 - OQ888150
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that a total of 3274 patients were enrolled and 2074 HIV-1 partial pol sequences were obtained.

Rationale: The paper provides the number of individuals who had samples obtained for HIV sequencing.

Answer: 2074
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were collected from patients living in Guangdong, China.

Rationale: The paper provides the country of origin for the sequenced samples.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were collected between Nov 1st, 2011 to Dec 31st, 2022.

Rationale: The paper provides the year range for the sequenced samples.

Answer: 2011-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning or any cloning-related terms.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the partial HIV-1 pol gene (HXB2 nt 2253--3252) was amplified.

Rationale: The paper provides information on the HIV gene that was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not Reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper provides information on the type of samples sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the study included patients who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper provides information on the treatment status of the individuals who had sequences obtained.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial or any trial-related terms.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the study included patients who had received ART for at least 6 months.

Rationale: The paper provides information on the treatment status of the individuals who had sequences obtained.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes or regimens.

Rationale: The paper does not provide information on the drug classes received by the individuals before sample sequencing.

Answer: Not Reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs or regimens.

Rationale: The paper does not provide information on the drugs received by the individuals before sample sequencing.

Answer: Not Reported
""""""",76
37554471,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" in the context of patient samples.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which suggests that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: The paper does not provide any information about making sequences publicly available, which suggests that they were not made available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions a single patient case.

Rationale: The paper explicitly mentions that the study is a case report, which suggests that only one individual had a sample obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sample.

Rationale: The paper does not provide any information about the country of origin for the sample, which suggests that it is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection, which suggests that it is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing methods.

Rationale: The paper does not provide any information about cloning or sequencing methods, which suggests that it is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic resistance testing"" but does not specify which genes were sequenced.

Rationale: The paper does not provide any information about which HIV genes were sequenced, which suggests that it is not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not provide any information about sequencing methods, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" as the source of the sample.

Rationale: The paper explicitly mentions that the sample was obtained from plasma, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient had a history of virological failure.

Rationale: The paper explicitly mentions that the patient had a history of virological failure, which suggests that sequences were obtained from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patient was not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient had a history of ARV treatment.

Rationale: The paper explicitly mentions that the patient had a history of ARV treatment, which suggests that sequences were obtained from an individual who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had received etravirine, dolutegravir, darunavir, and ritonavir.

Rationale: The paper explicitly mentions that the patient had received these drugs, which suggests that the drug classes received by the individual before sample sequencing were NNRTI, INSTI, and PI.

Answer: NNRTI, INSTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had received etravirine, dolutegravir, darunavir, and ritonavir.

Rationale: The paper explicitly mentions that the patient had received these drugs, which suggests that the drugs received by the individual before sample sequencing were etravirine, dolutegravir, darunavir, and ritonavir.

Answer: Etravirine, dolutegravir, darunavir, ritonavir",79
37573167,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, specifically on HIV-1 DNA extracted from whole-blood or lymphomonocytic cells. The paper also mentions that HIV-DNA genotypic resistance tests (GRT) were performed on virologically suppressed individuals.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, phenotypic susceptibility, or drug susceptibility assays. It only reports genotypic resistance testing and sequencing data.

Rationale: The paper does not meet the criteria for a ""Yes"" answer, as it does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). It also does not provide accession numbers for GenBank or any other database.

Rationale: The paper does not meet the criteria for a ""Yes"" answer, as it does not mention that sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers, so it is not possible to answer this question.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1126 individuals were included in the study, and that HIV-DNA GRT was performed on these individuals.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 1126

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Italy, and that samples were collected from several reference centers in Italy.

Rationale: The paper explicitly states the country where the samples were collected.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from 2010 to 2021.

Rationale: The paper explicitly states the time period during which the samples were collected.

Answer: 2010-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not meet the criteria for a ""Yes"" answer, as it does not mention cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that HIV-DNA GRT was performed, which typically involves sequencing the pol gene.

Rationale: The paper does not explicitly state which genes were sequenced, but based on the context, it is likely that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that HIV-1 DNA was extracted from whole-blood or lymphomonocytic cells.

Rationale: The paper explicitly states the type of samples that were sequenced.

Answer: Whole blood, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some individuals had a history of virological failure.

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it mentions that some individuals had a history of virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not meet the criteria for a ""Yes"" answer, as it does not mention a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some individuals were ART-experienced.

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some individuals were ART-experienced, but it does not specify which drug classes were received.

Rationale: The paper does not provide enough information to answer this question.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs that were received by individuals in the study.

Rationale: The paper does not provide enough information to answer this question.

Answer: Not reported",77
37574435,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that sequences were made publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 79 people with HIV (PWH) were included in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 79

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Taiwan.

Rationale: The paper explicitly mentions the country where the study was conducted, which meets the criteria for a geographical answer.

Answer: Taiwan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study period was from 1 January 2016 to 30 March 2022.

Rationale: The paper explicitly mentions the years during which the study was conducted, which meets the criteria for a temporal answer.

Answer: 2016-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any evidence of cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions the HIV genes that were sequenced, which meets the criteria for a specific answer.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method.

Rationale: The paper does not provide any evidence of a specific sequencing method, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""PBMC"".

Rationale: The paper explicitly mentions the types of samples that were sequenced, which meets the criteria for a specific answer.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not provide any evidence of a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""prior ARV exposure"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly mentions the drug classes that were received by individuals in the study before sample sequencing, which meets the criteria for a specific answer.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""bictegravir"", ""dolutegravir"", and ""emtricitabine"".

Rationale: The paper explicitly mentions the drugs that were received by individuals in the study before sample sequencing, which meets the criteria for a specific answer.

Answer: Bictegravir, Dolutegravir, Emtricitabine",83
37585352,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS)"" and that ""a long-range HIV genotyping protocol was used to generate viral sequences"".

Rationale: The paper explicitly mentions that HIV sequences were generated from patient samples using NGS and a long-range HIV genotyping protocol.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the prevalence of rilpivirine-associated resistance mutations (RPV-RAMs) in a cohort of people living with HIV-1 subtype C in Botswana, but does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""HIV-1 sequences are available on request through the PANGEA consortium (www.pangea-hiv.org)"".

Rationale: The paper explicitly mentions that the sequences are available on request through the PANGEA consortium.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 5805 (95.5%) proviral sequences from Botswana Combination Prevention Project (BCPP) participants"" were included in the analysis.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 5805

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from Botswana.

Rationale: The paper explicitly mentions the country of origin of the samples.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2013 and 2018.

Rationale: The paper explicitly mentions the years during which the samples were collected.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""near full-length HIV-1 pol sequences"" were generated.

Rationale: The paper explicitly mentions the HIV gene that was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""next-generation sequencing (NGS)"" was used.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""proviral DNA"" was sequenced.

Rationale: The paper explicitly mentions the type of sample that was sequenced.

Answer: Proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""samples from individuals experiencing virological failure were excluded"".

Rationale: The paper explicitly mentions that samples from individuals with virological failure were excluded.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was ""approved by the Institutional Review Boards (IRBs) at the US CDC and the Botswana Health Research and Development Committee IRB"" and that it is ""registered at ClinicalTrials.gov (NCT01965470)"".

Rationale: The paper explicitly mentions that the study was approved by IRBs and registered at ClinicalTrials.gov.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""patients received drugs belonging to a specific ARV class"" and that ""the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF)"".

Rationale: The paper explicitly mentions that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF)"".

Rationale: The paper explicitly mentions the drug classes that were received by the individuals in the study.

Answer: NNRTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF)"".

Rationale: The paper explicitly mentions the drugs that were received by the individuals in the study.

Answer: Efavirenz, emtricitabine, tenofovir",81
37593123,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly states that sequences were submitted to public databases, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide specific accession numbers, which makes it impossible to determine the exact accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 57,902 ART-naïve HIV-infected individuals had samples obtained for HIV sequencing.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 57,902

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were collected in China.

Rationale: The paper explicitly states the country where the samples were collected.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2022.

Rationale: The paper explicitly states the year range when the samples were collected.

Answer: 2004-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide information about cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning, which makes it impossible to determine whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 pol gene region was sequenced.

Rationale: The paper explicitly states the gene region that was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide information about the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which makes it impossible to determine the method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were sequenced.

Rationale: The paper explicitly states the type of sample that was sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that all sampled individuals were ART-naïve.

Rationale: The paper explicitly states that all sampled individuals were ART-naïve, which indicates that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information about clinical trials.

Rationale: The paper does not provide any information about clinical trials, which makes it impossible to determine whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that all sampled individuals were ART-naïve.

Rationale: The paper explicitly states that all sampled individuals were ART-naïve, which indicates that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that all sampled individuals were ART-naïve.

Rationale: The paper explicitly states that all sampled individuals were ART-naïve, which indicates that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that all sampled individuals were ART-naïve.

Rationale: The paper explicitly states that all sampled individuals were ART-naïve, which indicates that no drugs were received by individuals in the study before sample sequencing.

Answer: None",83
37626789,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"", and it does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that they are not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 551 HIV-positive children were included in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 551
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Ethiopia.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between 2017 and 2019.

Rationale: The paper explicitly mentions the years when the study was conducted, which suggests that the sequenced samples were obtained during this period.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the ""pol"" gene region of HIV-1 was sequenced.

Rationale: The paper explicitly mentions the gene region that was sequenced, which suggests that the ""pol"" gene was reported to have been sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that an ABI-3730 DNA genetic analyzer was used for sequencing.

Rationale: The paper explicitly mentions the sequencing method used, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that whole blood was collected from children and plasma was extracted using centrifugation.

Rationale: The paper explicitly mentions the type of sample that was sequenced, which suggests that plasma was sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that children with virologic failure (VL ≥ 1000 copies/mL) were included for HIV drug resistance investigation.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that children who had a history of ART exposure were included in the study.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that children received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions the drug classes that were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that children received AZT, 3TC, ABC, D4T, EFV, NVP, and LPV/r.

Rationale: The paper explicitly mentions the drugs that were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, ABC, D4T, EFV, NVP, LPV/r
""""""",81
37632026,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides the following accession numbers: MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, and OQ985493-OQ985958.

Rationale: The paper provides a list of accession numbers for the sequenced HIV isolates.

Answer: MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, and OQ985493-OQ985958

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 759 participants had samples obtained for HIV sequencing.

Rationale: The paper explicitly states that 759 participants had samples obtained for HIV sequencing.

Answer: 759

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was carried out in Cameroon.

Rationale: The paper explicitly states that the study was carried out in Cameroon, which suggests that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was carried out from November 2011 to August 2019.

Rationale: The paper explicitly states that the study was carried out from November 2011 to August 2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning or any cloning-related techniques, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol gene was sequenced.

Rationale: The paper explicitly states that the pol gene was sequenced, which suggests that the pol gene was the primary focus of the study.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that this was the primary sequencing method used in the study.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that plasma was the primary sample type used in the study.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that this was a primary focus of the study.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not part of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs, which suggests that this was a primary focus of the study.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that NRTIs, NNRTIs, and PIs were received by individuals in the study before sample sequencing.

Rationale: The paper explicitly states that NRTIs, NNRTIs, and PIs were received by individuals in the study before sample sequencing, which suggests that these were the primary drug classes used in the study.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that AZT, 3TC, FTC, ABC, TDF, EFV, NVP, LPV/r, ATV/r, and DRV/r were received by individuals in the study before sample sequencing.

Rationale: The paper explicitly states that these drugs were received by individuals in the study before sample sequencing, which suggests that these were the primary drugs used in the study.

Answer: AZT, 3TC, FTC, ABC, TDF, EFV, NVP, LPV/r, ATV/r, DRV/r",91
37632071,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that a total of 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0, and 197 patients were included in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 197
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted at 4 Italian Infectious Diseases Units.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in the period 2019-2022.

Rationale: The paper explicitly mentions the years when the study was conducted, which suggests that the sequenced samples were obtained during this period.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma HIV RNA was extracted from plasma.

Rationale: The paper explicitly mentions the type of sample that was sequenced, which suggests that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some patients had virological failure before switching to BIC/FTC/TAF.

Rationale: The paper explicitly mentions that some patients had virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients were ART-experienced.

Rationale: The paper explicitly mentions that some patients were ART-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients were on INSTI-based regimens before switching to BIC/FTC/TAF.

Rationale: The paper explicitly mentions the drug class that some patients were on before switching, which suggests that INSTI-based regimens were used.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients were on INSTI-based regimens before switching to BIC/FTC/TAF.

Rationale: The paper explicitly mentions the drug class that some patients were on before switching, but it does not provide specific drug names.

Answer: Not reported
""""""",80
37649807,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, and it focuses on sequencing and phylogenetics.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, and it does not mention that sequences were submitted to GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that a total of 793,902 records from clients aged ≥15 years who initiated ART during 2015-2021 had all VL tests done using plasma and had at least one VL after 24 weeks on ART.

Rationale: The paper provides information on the number of individuals who had samples obtained for HIV sequencing.

Answer: 793,902

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Kenya.

Rationale: The paper explicitly mentions that the study was conducted in Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study included data from 2015 to 2021.

Rationale: The paper provides information on the years during which the samples were obtained.

Answer: 2015-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any evidence of cloning, and it does not mention any cloning-related techniques.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper does not provide any information on which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any sequencing methods.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some patients had virological failure.

Rationale: The paper provides information on virological failure, which indicates that some sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any evidence of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some patients were ART-experienced.

Rationale: The paper provides information on ART-experienced patients, which indicates that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper provides information on the drug classes received by patients before sample sequencing.

Answer: NRTIs, NNRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received TDF, 3TC, FTC, EFV, and DTG.

Rationale: The paper provides information on the specific drugs received by patients before sample sequencing.

Answer: TDF, 3TC, FTC, EFV, DTG",76
37662576,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genetic sequencing were performed on clinical samples"" and ""genotypic resistance testing"" was done on ""patient samples"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"" and reports values such as IC50 and EC50.

Rationale: The paper explicitly states that phenotypic susceptibility and drug susceptibility assays were performed, and reports values such as IC50 and EC50, which indicates that in vitro drug susceptibility data is reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that sequences were submitted to ""GenBank"" and reports accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank and reports accession numbers, which indicates that sequences from the paper were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers such as ""6DGX"" and ""2PC0"".

Rationale: The paper explicitly reports accession numbers, which can be used to retrieve the sequences from GenBank.

Answer: 6DGX, 2PC0

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly report the number of individuals.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly report the countries.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly report the years.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly report cloning.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""protease sequencing"".

Rationale: The paper explicitly states that pol genotyping/sequencing and protease sequencing were performed, which indicates that the pol gene, specifically the protease region, was sequenced.

Answer: Pol, PR

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""molecular dynamics simulations"" and ""comparative dynamics analysis"".

Rationale: The paper does not explicitly report the sequencing method used, but mentions molecular dynamics simulations and comparative dynamics analysis, which suggests that a computational approach was used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""clinical samples"" and ""patient samples"".

Rationale: The paper does not provide information on the specific type of samples sequenced, but mentions clinical samples and patient samples.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""drug-resistant mutations"".

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen, which indicates that sequences from individuals with virological failure were obtained.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly report a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""drug-resistant mutations"" and ""antiretroviral therapy"".

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs, which indicates that sequences from individuals who had previously received ARV drugs were obtained.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""protease inhibitors"" and ""darunavir"".

Rationale: The paper explicitly states that protease inhibitors, specifically darunavir, were received by individuals in the study before sample sequencing.

Answer: PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""darunavir"" and ""lopinavir"".

Rationale: The paper explicitly states that darunavir and lopinavir were received by individuals in the study before sample sequencing.

Answer: Darunavir, Lopinavir",79
37674678,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also does not provide accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 1, 2019 and November 31, 2021 were enrolled in this study.

Rationale: The paper explicitly mentions the number of participants who had samples obtained for HIV sequencing.

Answer: 1,393

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Nanjing, China.

Rationale: The paper explicitly mentions the location where the study was conducted, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between January 1, 2019 and November 31, 2021.

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about cloning prior to sequencing.

Rationale: The paper does not provide any information about the sequencing workflow, which suggests that cloning prior to sequencing is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the target fragment of 1,059 bp in the pol gene (HXB2:2253--3,312) was amplified using nested polymerase chain reaction (PCR).

Rationale: The paper explicitly mentions the gene that was sequenced, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide any information about the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma.

Rationale: The paper explicitly mentions the type of sample that was sequenced, which suggests that plasma samples were used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the participants were ART-naïve, which suggests that they had not received any treatment prior to the study.

Rationale: The paper explicitly mentions that the participants were ART-naïve, which suggests that they did not have virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the participants were ART-naïve, which suggests that they had not received any ARV drugs prior to the study.

Rationale: The paper explicitly mentions that the participants were ART-naïve, which suggests that they had not received any ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the drug classes received by the individuals.

Rationale: The paper does not provide any information about the drug classes, which suggests that they are not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the drugs received by the individuals.

Rationale: The paper does not provide any information about the drugs, which suggests that they are not reported.

Answer: Not reported",89
37701387,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""sequencing"" in the context of patient samples.

Rationale: The paper discusses the use of HIV sequencing in the context of patient samples, which suggests that it reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions a study with 30 participants (Table 1).

Rationale: The paper provides information about the number of participants in the study.

Answer: 30

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Italy.

Rationale: The paper provides information about the country where the study was conducted.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from May 2020 to December 2021.

Rationale: The paper provides information about the time period when the study was conducted.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the study used plasma samples.

Rationale: The paper provides information about the type of samples used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: The paper does not provide any information about virological failure or treatment regimens.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a pilot, single-center, single-arm, prospective, phase IV clinical trial.

Rationale: The paper provides information about the study design, which suggests that it was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information about previous ARV drug use.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs.

Answer: Not reported",64
37716367,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention ""genotypic resistance testing"" and ""HIV sequencing"" in the context of studying HIV drug resistance.

Rationale: Based on the evidence, it appears that the paper does report HIV sequences from patient samples, as it mentions genotypic resistance testing and HIV sequencing. However, the paper does not provide explicit information about the type of samples used or the sequencing methods employed.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms such as ""phenotypic susceptibility"" or ""drug susceptibility assay"".

Rationale: Based on the evidence, it appears that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available or depositing them in a public database.

Rationale: Based on the evidence, it appears that the sequences from the paper were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: Based on the evidence, it appears that the paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: Based on the evidence, it appears that the paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: Based on the evidence, it appears that the paper does not provide information about the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: Based on the evidence, it appears that the paper does not provide information about cloning samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: Based on the evidence, it appears that the paper does not provide information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: Based on the evidence, it appears that the paper does not provide information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: Based on the evidence, it appears that the paper does not provide information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: Based on the evidence, it appears that the paper does not provide information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the evidence, it appears that the paper does not provide information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ARV drugs or treatment history.

Rationale: Based on the evidence, it appears that the paper does not provide information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention drug classes or treatment regimens.

Rationale: Based on the evidence, it appears that the paper does not provide information about drug classes received by individuals in the study before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs or treatment regimens.

Rationale: Based on the evidence, it appears that the paper does not provide information about specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported",78
37755428,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about making the sequences publicly available, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 143 infants had remnant specimens available for HIVDR testing.

Rationale: The paper explicitly states that 143 infants had remnant specimens available for HIVDR testing, which meets the criteria for a numerical answer.

Answer: 143
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Haiti.

Rationale: The paper explicitly states that the study was conducted in Haiti, which meets the criteria for a geographical answer.

Answer: Haiti
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted between April 2020 and March 2021.

Rationale: The paper explicitly states that the study was conducted between April 2020 and March 2021, which meets the criteria for a temporal answer.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the integrase coding region of pol was sequenced.

Rationale: The paper explicitly states that the integrase coding region of pol was sequenced, which meets the criteria for a specific gene answer.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that a Sanger-based method was used for sequencing.

Rationale: The paper explicitly states that a Sanger-based method was used for sequencing, which meets the criteria for a specific method answer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that dried blood spot specimens were used for sequencing.

Rationale: The paper explicitly states that dried blood spot specimens were used for sequencing, which meets the criteria for a specific sample type answer.

Answer: DBS
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that one infant had a detected DTG resistance, but it does not explicitly state that the infant had virological failure on a treatment regimen.

Rationale: The paper does not provide enough information to determine if the infant had virological failure on a treatment regimen, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the mother of the infant was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the mother of the infant was receiving ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the mother of the infant was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the mother of the infant was receiving NRTIs and INSTIs, which meets the criteria for a specific drug class answer.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the mother of the infant was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the mother of the infant was receiving tenofovir, lamivudine, and dolutegravir, which meets the criteria for a specific drug answer.

Answer: Tenofovir, Lamivudine, Dolutegravir
""""""",83
37775947,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, specifically plasma samples. The paper also mentions that the sequencing was done to detect pre-existing drug resistance.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms such as ""phenotypic susceptibility"", ""drug susceptibility assay"", or ""IC50"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to a public database or made available in a sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1380 participants had samples obtained for HIV sequencing.

Rationale: The paper explicitly states the number of participants who had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 1380

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in multiple countries, but does not provide a specific list of countries.

Rationale: The paper does not provide a specific list of countries, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2009 and 2013.

Rationale: The paper explicitly states the years during which the study was conducted, which meets the criteria for a numerical answer.

Answer: 2009-2013

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms such as ""amplicons were cloned and sequenced"" or ""TA cloning/Topo TA cloning was performed"".

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol gene was sequenced, specifically the protease and reverse transcriptase regions.

Rationale: The paper explicitly states the genes that were sequenced, which meets the criteria for a specific answer.

Answer: Pol (protease and reverse transcriptase regions)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that next-generation sequencing (NGS) was used, specifically the Illumina MiSeq platform.

Rationale: The paper explicitly states the sequencing method used, which meets the criteria for a specific answer.

Answer: NGS (Illumina MiSeq)

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were sequenced.

Rationale: The paper explicitly states the type of samples that were sequenced, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some participants experienced virological failure, but does not specify whether sequences were obtained from these individuals.

Rationale: The paper does not provide clear information about whether sequences were obtained from individuals with virological failure, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized clinical trial.

Rationale: The paper explicitly states that the study was a clinical trial, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some participants were treatment-experienced, but does not specify whether they had previously received ARV drugs.

Rationale: The paper does not provide clear information about whether the participants had previously received ARV drugs, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information about the specific drug classes received by the participants.

Rationale: The paper does not provide any information about the drug classes received by the participants, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information about the specific drugs received by the participants.

Rationale: The paper does not provide any information about the specific drugs received by the participants, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported",84
37817087,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots"" and that ""genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""all datasets including sequences are available from the corresponding author upon reasonable request"".

Rationale: Although the paper does not explicitly state that the sequences were submitted to a public database, it does indicate that the sequences are available upon request, which suggests that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""PR and RT sequences were obtained from 4559 (39.6%) cases, and PR, RT and IN sequences were obtained from 3097 (26.9%) cases"".

Rationale: The paper explicitly states that samples were obtained from 4559 individuals for PR and RT sequencing, and from 3097 individuals for PR, RT, and IN sequencing.

Answer: 4559 (PR and RT), 3097 (PR, RT, and IN)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from Germany.

Rationale: The paper explicitly states that the samples were obtained from Germany, which suggests that the country of origin is Germany.

Answer: Germany

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from 2017 to 2020.

Rationale: The paper explicitly states that the samples were obtained from 2017 to 2020, which suggests that the year range is 2017-2020.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the genomic regions of protease (PR, amino acids 9--99), reverse transcriptase (RT, amino acids 1-252) and integrase (IN, amino acids 1-279) were amplified"".

Rationale: The paper explicitly states that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""the amplicons were sequenced using an Illumina NGS method (MiSeq)"".

Rationale: The paper explicitly states that the sequencing method used was Illumina NGS (MiSeq), which suggests that the method was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was isolated from the sample material (serum, plasma or spot elution)"".

Rationale: The paper explicitly states that the samples were serum, plasma, or spot elution, which suggests that the sample types were plasma and serum.

Answer: Plasma, serum

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: The paper does not provide any information about virological failure or treatment regimens, which suggests that the sequences were not obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention clinical trials or any trial-related information.

Rationale: The paper does not provide any information about clinical trials, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ARV drugs or any treatment-related information.

Rationale: The paper does not provide any information about ARV drugs or treatment, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes or treatment-related information.

Rationale: The paper does not provide any information about drug classes or treatment, which suggests that the individuals did not receive any drug classes before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs or treatment-related information.

Rationale: The paper does not provide any information about specific drugs or treatment, which suggests that the individuals did not receive any specific drugs before sample sequencing.

Answer: None",90
37823653,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots"" and ""genetic sequencing was performed on clinical samples from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH or patient cohorts.""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" and does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"" and does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 6,078 HIV-1 near full length sequences were generated for the BCPP study"" and ""1,282 participants were ART naïve and 4,748 were ART experienced"".

Rationale: The paper explicitly states that 6,078 individuals had samples obtained for HIV sequencing.

Answer: 6,078

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""participants were randomly selected to participate in the Botswana Combination Prevention Project (BCPP)"".

Rationale: The paper explicitly states that the samples were obtained from Botswana.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""participants were enrolled between 2013 and 2018"".

Rationale: The paper explicitly states that the samples were obtained between 2013 and 2018.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that cloning was not performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the generated sequences were from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana who were randomly selected to participate in the Botswana Combination Prevention Project (BCPP)"" and ""Viral sequences were generated by a long-range HIV genotyping protocol described elsewhere (24, 27) with minor modifications that included a reduced annealing temperature (58°C instead of 62°C) as a backup amplification strategy and using the first-round amplicon as a template for next-generation sequencing (NGS)"".

Rationale: The paper does not explicitly state which HIV genes were sequenced, but it mentions that the sequences were generated using a long-range HIV genotyping protocol, which suggests that the sequences may have included multiple genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""the NGS was performed by the Biopolimers Facility at Harvard Medical School (https://genome.med.harvard.edu/) and through collaboration with PANGEA HIV consortium (24) at the Wellcome Trust Sanger Institute (Cambridge, UK; http://www.sanger.ac.uk/) with high-sequencing coverage and using Illumina platform MiSeq and HiSeq"".

Rationale: The paper explicitly states that next-generation sequencing (NGS) was used for sequencing, specifically using the Illumina platform.

Answer: NGS (Illumina platform)

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""proviral DNA templates were used for amplification, as the majority of participants were receiving ART"".

Rationale: The paper explicitly states that proviral DNA templates were used for amplification, which suggests that the samples were obtained from peripheral blood mononuclear cells (PBMCs).

Answer: PBMCs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""213 (4.5%) had virologic failure (VF) (VL >400)"".

Rationale: The paper explicitly states that some individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""this study has been registered at ClinicalTrials.gov under registration no. NCT01965470"".

Rationale: The paper explicitly states that the study was registered at ClinicalTrials.gov, which suggests that it was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""4,748 were ART experienced"".

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016"".

Rationale: The paper explicitly states that some individuals received NNRTI-based ART, which suggests that they received NNRTI drugs.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016"".

Rationale: The paper explicitly states that some individuals received efavirenz or nevirapine, which are NNRTI drugs.

Answer: Efavirenz, nevirapine",104
37872202,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genetic sequencing were performed on clinical samples such as plasma, serum, PBMC, proviral DNA, or dried blood spots"" and ""genotypic resistance testing, HIV sequencing, Sanger, Illumina MiSeq, single-genome sequencing"".

Rationale: The paper explicitly mentions the use of clinical samples and various sequencing methods, indicating that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay"" and ""cell-based susceptibility assays are described (e.g., TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293) with drug titrations and reporter readouts (luciferase, p24, RT activity)"".

Rationale: The paper explicitly mentions the use of phenotypic susceptibility assays and cell-based susceptibility assays, indicating that in vitro drug susceptibility data is reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions ""sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA)"" and ""accession numbers for GenBank or any of the above databases"".

Rationale: The paper explicitly mentions the submission of sequences to public databases and the availability of accession numbers, indicating that sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers.

Rationale: The paper does not provide specific GenBank accession numbers, but mentions that sequences were submitted to GenBank.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide specific information on the number of individuals.

Rationale: The paper does not provide specific information on the number of individuals, but mentions that samples were obtained from patients.

Answer: Not Reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Thailand"" as the country where the study was conducted.

Rationale: The paper explicitly mentions Thailand as the country where the study was conducted, indicating that samples were obtained from Thailand.

Answer: Thailand

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide specific information on the years.

Rationale: The paper does not provide specific information on the years, but mentions that the study was conducted.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide specific information on cloning.

Rationale: The paper does not provide specific information on cloning, but mentions the use of various sequencing methods.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""env"".

Rationale: The paper explicitly mentions the use of pol genotyping/sequencing and env, indicating that these genes were sequenced.

Answer: Pol, Env

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina MiSeq"".

Rationale: The paper explicitly mentions the use of Sanger sequencing and Illumina MiSeq, indicating that these methods were used for sequencing.

Answer: Sanger sequencing, Illumina MiSeq

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"".

Rationale: The paper explicitly mentions the use of plasma and PBMC, indicating that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment-experienced"".

Rationale: The paper explicitly mentions virological failure and treatment-experienced, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide specific information on clinical trials.

Rationale: The paper does not provide specific information on clinical trials, but mentions that the study was conducted.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" and ""ARV drugs"".

Rationale: The paper explicitly mentions treatment-experienced and ARV drugs, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly mentions these drug classes, indicating that they were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""zidovudine"", ""lamivudine"", ""efavirenz"", and ""raltegravir"".

Rationale: The paper explicitly mentions these specific drugs, indicating that they were received by individuals in the study before sample sequencing.

Answer: Zidovudine, Lamivudine, Efavirenz, Raltegravir",91
37878637,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, specifically on plasma samples. The paper also mentions that HIV-1 RNA was extracted from plasma aliquots and sequenced using the Applied Biosystems 3500 genetic analyzer.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related experiments.

Rationale: The paper focuses on sequencing and phylogenetic analysis of HIV-1 strains, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that the data underlying the results presented in the study are available from figshare (https://doi.org/10.6084/m9.figshare.22779836).

Rationale: The paper explicitly states that the data are available from figshare, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 141 participants with PVL ≥ 1000 RNA copies/mL, and whose samples were successfully sequenced were included in the current assessment.

Rationale: The paper explicitly states that 141 participants had samples obtained for HIV sequencing.

Answer: 141

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper explicitly states that the study was conducted in Cameroon, which meets the criteria for a ""Yes"" answer.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from 2018-2020.

Rationale: The paper explicitly states that the study was conducted from 2018-2020, which meets the criteria for a ""Yes"" answer.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the protease and reverse transcriptase regions were sequenced.

Rationale: The paper explicitly states that the protease and reverse transcriptase regions were sequenced, which meets the criteria for a ""Yes"" answer.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the Applied Biosystems 3500 genetic analyzer was used for sequencing.

Rationale: The paper explicitly states that the Applied Biosystems 3500 genetic analyzer was used for sequencing, which meets the criteria for a ""Yes"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which meets the criteria for a ""Yes"" answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants with virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included participants with virological failure on a treatment regimen, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included participants who had previously received ARV drugs.

Rationale: The paper explicitly states that the study included participants who had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states that the participants received NRTIs, NNRTIs, and PIs, which meets the criteria for a ""Yes"" answer.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants received specific ARV drugs such as 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir.

Rationale: The paper explicitly states that the participants received specific ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",91
37880705,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions that sequences were retrieved from GenBank.

Rationale: The paper explicitly states that it analyzed HIV-1 pol sequences from studies conducted among ART-naïve Ethiopian individuals, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper focuses on sequencing, phylogenetics, and epidemiology, but it does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that sequences were retrieved from GenBank, but it does not provide any accession numbers.

Rationale: Although the paper does not provide accession numbers, it mentions that sequences were retrieved from GenBank, which suggests that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any accession numbers, and it only mentions that sequences were retrieved from GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1070 sequences were analyzed.

Rationale: The paper does not explicitly state the number of individuals, but it mentions that 1070 sequences were analyzed, which suggests that at least 1070 individuals had samples obtained for HIV sequencing.

Answer: 1070

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Ethiopia.

Rationale: The paper explicitly states that the study was conducted in Ethiopia, which indicates that the sequenced samples were obtained from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study analyzed sequences from 2003 to 2018.

Rationale: The paper explicitly states that the study analyzed sequences from 2003 to 2018, which indicates that the sequenced samples were obtained during this time period.

Answer: 2003-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that HIV-1 pol sequences were analyzed.

Rationale: The paper explicitly states that HIV-1 pol sequences were analyzed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which makes it difficult to determine the answer.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study analyzed sequences from ART-naïve individuals.

Rationale: The paper explicitly states that the study analyzed sequences from ART-naïve individuals, which suggests that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study analyzed sequences from ART-naïve individuals.

Rationale: The paper explicitly states that the study analyzed sequences from ART-naïve individuals, which suggests that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes or specific drugs.

Rationale: The paper does not provide any information about drug classes or specific drugs, which makes it difficult to determine the answer.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs.

Rationale: The paper does not provide any information about specific drugs, which makes it difficult to determine the answer.

Answer: Not reported",76
37896785,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region."" and ""The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382 ).""

Rationale: The paper explicitly states that HIV-1 genotyping and mutation detection were performed on patient samples, and the nucleotide sequences of the *pol* gene region were obtained and deposited in GenBank.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV-1 genetic sequences and the detection of drug resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382 ).""

Rationale: The paper explicitly states that the nucleotide sequences of the HIV-1 samples were deposited in GenBank, making them publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382 ).""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ215322-OQ215382

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City with a viral load above 500 copies per ml of blood plasma.""

Rationale: The paper explicitly states that 61 pregnant women had samples obtained for HIV sequencing.

Answer: 61

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City...""

Rationale: The paper explicitly states that the samples were collected in Ho Chi Minh City, which is located in Vietnam.

Answer: Vietnam

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""The study material was blood plasma samples collected in 2021...""

Rationale: The paper explicitly states that the samples were collected in 2021.

Answer: 2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.""

Rationale: The paper explicitly states that the *pol* gene region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sequencing reaction products were analyzed using an ABI Prism 3500 genetic analyzer (Applied Biosystems, Waltham, MA, USA).""

Rationale: The paper explicitly states that an ABI Prism 3500 genetic analyzer was used for sequencing, which is a Sanger sequencing platform.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""The study material was blood plasma samples...""

Rationale: The paper explicitly states that blood plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""31 women showed virological failure of ART...""

Rationale: The paper explicitly states that some of the individuals had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""31 women showed virological failure of ART...""

Rationale: The paper explicitly states that some of the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs.

Answer: Not Reported",80
37896860,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 704 children were enrolled in the study, and it states that 106 participants had drug resistance testing (DRT) results.

Rationale: The paper explicitly mentions the number of participants who had DRT results, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 106
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Kenya.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that this is the country where the sequenced samples were obtained.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from March 2019 to December 2020.

Rationale: The paper explicitly mentions the years when the study was conducted, which suggests that these are the years when the sequenced samples were obtained.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the study focused on the pol gene, and it specifically mentions the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions the pol gene and the protease and reverse transcriptase regions, which suggests that these are the HIV genes that were reported to have been sequenced.

Answer: Pol, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which suggests that this is the method that was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions plasma samples, which suggests that these are the type of samples that were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study focused on children with virological failure on antiretroviral treatment.

Rationale: The paper explicitly mentions virological failure on antiretroviral treatment, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a randomized controlled trial.

Rationale: The paper explicitly mentions a randomized controlled trial, which suggests that the patients in the study were in a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study focused on children who were on antiretroviral treatment.

Rationale: The paper explicitly mentions antiretroviral treatment, which suggests that the individuals in the study had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study focused on children who were on antiretroviral treatment, and it specifically mentions NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions NRTIs, NNRTIs, and PIs, which suggests that these are the drug classes that were received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study focused on children who were on antiretroviral treatment, and it specifically mentions lamivudine, abacavir, zidovudine, lopinavir/ritonavir, and efavirenz.

Rationale: The paper explicitly mentions these drugs, which suggests that they were received by individuals in the study before sample sequencing.

Answer: Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz
""""""",89
37910452,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not provide any information about HIV sequences from patient samples. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about in vitro drug susceptibility data. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about making sequences publicly available. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about cloning prior to sequencing. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were reported to have been sequenced. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about which HIV genes were reported to have been sequenced. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the method used for sequencing. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the type of samples that were sequenced. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients were in a clinical trial. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about HIV sequences from individuals who had previously received ARV drugs. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing. It discusses the prevalence of adherence to ART among HIV patients in Ghana.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing. It focuses on the prevalence of adherence to ART among HIV patients in Ghana.

Answer: Not reported
""""""",98
37914679,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples"" and that ""HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020, with drug-sensitive results from traditional pre-existing drug resistance test, were enrolled in this study.""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform.""

Rationale: The paper explicitly states that 76 patients had samples obtained for HIV sequencing, which meets the criteria for a numerical answer.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted at the Second Hospital of Nanjing, which is located in China.

Rationale: The paper explicitly states that the study was conducted in China, which meets the criteria for a geographical answer.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from January 1, 2018 to December 31, 2020.

Rationale: The paper explicitly states the time period during which the samples were obtained, which meets the criteria for a temporal answer.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the pol region encompassing protease and reverse transcriptase"" was sequenced.

Rationale: The paper explicitly states that the pol region, including protease and reverse transcriptase, was sequenced, which meets the criteria for a specific answer.

Answer: Pol (including PR and RT)

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the MiSeq second-generation sequencing platform was used.

Rationale: The paper explicitly states that the MiSeq platform was used, which meets the criteria for a specific answer.

Answer: NGS (MiSeq)

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma pre-existing low-frequency drug resistance mutations"" were detected.

Rationale: The paper explicitly states that plasma samples were sequenced, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""38 patients who failed antiviral therapy were defined as the failure group.""

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""38 patients who failed antiviral therapy"" were included in the study.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the initial treatment regimen of patients in this study population was predominantly 2NRTI + NNRTI.""

Rationale: The paper explicitly states that the initial treatment regimen included 2NRTI + NNRTI, which meets the criteria for a specific answer.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drugs received by individuals in the study.

Rationale: The paper does not provide specific information about the drugs received, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported",83
37920909,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples"" and that ""HIV-1 integrase genes of 601 cases were sequenced successfully"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""629 ART-naïve individuals"" were recruited for the study and that ""HIV-1 integrase genes of 601 cases were sequenced successfully"".

Rationale: The paper explicitly states that 601 individuals had samples obtained for HIV sequencing.

Answer: 601

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Tianjin, China.

Rationale: The paper explicitly states that the study was conducted in Tianjin, China, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between January 1, 2020, and April 1, 2023.

Rationale: The paper explicitly states that the study was conducted between 2020 and 2023, which suggests that the samples were obtained during this time period.

Answer: 2020-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""HIV-1 integrase genes"" were sequenced.

Rationale: The paper explicitly states that HIV-1 integrase genes were sequenced, which suggests that the IN gene was targeted.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""standard Sanger sequencing"" was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that this method was employed for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not explicitly state the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced, which suggests that this information is not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ""ART-naïve individuals"", which suggests that the individuals did not experience virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included ART-naïve individuals, which suggests that the individuals did not experience virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any related terms.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ""ART-naïve individuals"", which suggests that the individuals did not previously receive ARV drugs.

Rationale: The paper explicitly states that the study included ART-naïve individuals, which suggests that the individuals did not previously receive ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes or ARV drugs.

Rationale: The paper does not provide any information about drug classes or ARV drugs, which suggests that this information is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs.

Rationale: The paper does not provide any information about specific drugs, which suggests that this information is not reported.

Answer: Not reported",78
37938856,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 820 women were enrolled in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 820

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Kenya.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from 2019 to 2022.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""pol genotyping/sequencing"" was performed.

Rationale: The paper explicitly mentions that ""pol genotyping/sequencing"" was performed, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which suggests that this was the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing, which suggests that this was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some participants had virological failure.

Rationale: The paper explicitly mentions that some participants had virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some participants were ART-experienced.

Rationale: The paper explicitly mentions that some participants were ART-experienced, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that some participants received NRTIs, NNRTIs, and PIs, which suggests that these were the drug classes received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants received specific ARV drugs such as 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir.

Rationale: The paper explicitly mentions that some participants received specific ARV drugs, which suggests that these were the drugs received by individuals in the study before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",91
37941373,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any evidence that the sequences were made publicly available, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that samples were obtained from 1032 patients.

Rationale: The paper explicitly states that samples were obtained from 1032 patients, which meets the criteria for a numerical answer.

Answer: 1032

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Chongqing, China.

Rationale: The paper explicitly states that the study was conducted in Chongqing, China, which meets the criteria for a geographical answer.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from July 2019 to August 2022.

Rationale: The paper explicitly states that the study was conducted from July 2019 to August 2022, which meets the criteria for a temporal answer.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any evidence of cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the integrase coding region of the pol gene was sequenced.

Rationale: The paper explicitly states that the integrase coding region of the pol gene was sequenced, which meets the criteria for a specific gene answer.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which meets the criteria for a specific sequencing method answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which meets the criteria for a specific sample type answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that some patients had virological failure on a treatment regimen.

Rationale: The paper explicitly states that some patients had virological failure on a treatment regimen, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any evidence of a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that some patients had previously received ARV drugs.

Rationale: The paper explicitly states that some patients had previously received ARV drugs, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper explicitly states that some patients received NRTIs, NNRTIs, and INSTIs, which meets the criteria for a specific drug class answer.

Answer: NRTIs, NNRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received specific drugs such as dolutegravir, rilpivirine, lamivudine, and tenofovir.

Rationale: The paper explicitly states that some patients received specific drugs such as dolutegravir, rilpivirine, lamivudine, and tenofovir, which meets the criteria for a specific drug answer.

Answer: Dolutegravir, rilpivirine, lamivudine, tenofovir",85
37946329,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic drug resistance testing was performed as described previously"" and that ""the partial pol gene sequence was successfully amplified in 921 out of 1078 patients, and the INT gene was analyzed in 751 patients.""

Rationale: The paper mentions that genotypic drug resistance testing was performed on patient samples, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""antiretroviral susceptibility was analyzed by submitting the identified sequences to the Stanford HIV-1 drug resistance database"" and that ""the incidence of drug resistance was higher in males than females"".

Rationale: The paper mentions that antiretroviral susceptibility was analyzed, but it does not provide in vitro drug susceptibility data. Instead, it uses a database to predict susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to a public database or made available.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 921 HIV-1 patients"" were included in the study.

Rationale: The paper mentions that 921 patients were included in the study, which suggests that samples were obtained from 921 individuals.

Answer: 921

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Henan Province, China.

Rationale: The paper mentions that the study was conducted in Henan Province, China, which suggests that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from June 2018 to April 2022.

Rationale: The paper mentions that the study was conducted from June 2018 to April 2022, which suggests that the samples were obtained during this time period.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the partial pol gene sequence was successfully amplified in 921 out of 1078 patients, and the INT gene was analyzed in 751 patients.""

Rationale: The paper mentions that the partial pol gene sequence and the INT gene were analyzed, which suggests that the pol and INT genes were sequenced.

Answer: Pol, INT

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and that ""the partial pol gene sequence was successfully amplified in 921 out of 1078 patients"".

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""the incidence of drug resistance was higher in males than females"" and that ""the incidence of DRMs was the highest in patients with NNRTI-based regimens"".

Rationale: The paper mentions that the incidence of drug resistance was higher in certain groups, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""the incidence of DRMs was the highest in patients with NNRTI-based regimens"" and that ""the incidence of DRMs was higher in males than females"".

Rationale: The paper mentions that the incidence of drug resistance was higher in certain groups, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the incidence of DRMs was the highest in patients with NNRTI-based regimens"" and that ""the incidence of DRMs was higher in males than females"".

Rationale: The paper mentions that the incidence of drug resistance was higher in patients with NNRTI-based regimens, which suggests that NNRTIs were received by individuals in the study before sample sequencing.

Answer: NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs.

Answer: Not reported",83
37957382,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper mentions specific sequencing methods and reports GenBank accession numbers, further supporting the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions that sequences were submitted to public databases and reports accession numbers, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide specific accession numbers, which makes it impossible to determine the exact accession numbers.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 8 individuals.

Rationale: The paper explicitly mentions that sequencing was performed on samples from 8 individuals, which indicates that 8 individuals had samples obtained for HIV sequencing.

Answer: 8

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained, which makes it impossible to determine the countries.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the samples were obtained, which makes it impossible to determine the years.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which makes it impossible to determine whether samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""pol genotyping/sequencing"" was performed, which suggests that the pol gene was sequenced.

Rationale: The paper explicitly mentions that pol genotyping/sequencing was performed, which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger sequencing"" was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which indicates that this was the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""plasma"" samples were sequenced.

Rationale: The paper explicitly mentions that plasma samples were sequenced, which indicates that this was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with ""virological failure"" on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which indicates that this was the case.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about clinical trials, which makes it impossible to determine whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs, which indicates that this was the case.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing, which makes it impossible to determine the drug classes.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing, which makes it impossible to determine the drugs.

Answer: Not Reported",96
37966701,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"" but does not explicitly state that genetic sequencing was performed on clinical samples from patients.

Rationale: Although the paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, it does mention ""genotypic resistance testing"" and ""HIV sequencing"", which suggests that HIV sequences from patient samples were reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""321 individuals received at least one continuation CAB + RPV LA injection during the study period"".

Rationale: Although the paper does not explicitly state that HIV sequencing was performed on these individuals, it can be inferred that the samples were obtained from these individuals.

Answer: 321

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in the US.

Rationale: The paper explicitly states that the study was conducted in the US.

Answer: USA

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study period was from 21 January 2021 to 15 March 2022.

Rationale: The paper explicitly states the study period.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: Not available.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: Not available.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""four confirmed virologic failures were observed"".

Rationale: The paper explicitly states that virologic failures were observed, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""patients received CAB + RPV LA injectable"".

Rationale: The paper explicitly states that patients received CAB + RPV LA injectable, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""CAB + RPV LA injectable"" was received by the patients.

Rationale: The paper explicitly states that CAB + RPV LA injectable was received by the patients, which suggests that they received INSTI and NNRTI drug classes.

Answer: INSTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""CAB + RPV LA injectable"" was received by the patients.

Rationale: The paper explicitly states that CAB + RPV LA injectable was received by the patients.

Answer: Cabotegravir, Rilpivirine",72
37973713,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and the methods mention ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, and the methods focus on sequencing and genotyping.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information on the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 117 patients were recruited for the study.

Rationale: The paper explicitly mentions the number of patients recruited for the study, which meets the criteria for a numerical answer.

Answer: 117

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that samples were obtained from Poland and Ukraine.

Rationale: The paper explicitly mentions the countries where the samples were obtained, which meets the criteria for a geographical answer.

Answer: Poland, Ukraine

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2020 and 2022.

Rationale: The paper explicitly mentions the years when the study was conducted, which meets the criteria for a temporal answer.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on cloning prior to sequencing, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the protease and reverse transcriptase coding regions were sequenced.

Rationale: The paper explicitly mentions the genes that were sequenced, which meets the criteria for a specific answer.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was used.

Rationale: The paper explicitly mentions the sequencing method used, which meets the criteria for a specific answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the type of samples used for sequencing, which meets the criteria for a specific answer.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information on virological failure on a treatment regimen, which meets the criteria for a ""No"" answer.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some patients were ART-naive, while others were ART-experienced.

Rationale: The paper explicitly mentions that some patients were ART-experienced, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information on specific drug classes, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information on specific drugs, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported",74
37976080,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Viral RNA was extracted from 200 µL plasma samples using the QIAamp viral RNA mini kit (Qiagen, Hilton, Germany) according to the operational instructions. Extracted RNA was used for first-round polymerase chain reaction, and the products were used for second-round polymerase chain reaction amplification; both rounds were performed in 25 µL volume reactions to amplify the HIV pol gene region (HXB2: 2253-3553 nt). This covered the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids).""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, specifically plasma samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the deposition of sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 2869 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions, thus yielding a final sample size of 2568.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 2568

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""We selected 8 provincial-level administrative divisions (PLADs) in China as the study area to conduct a large multicenter observational cross-sectional study.""

Rationale: The paper explicitly states that the samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Recruitment and specimen collection of HIV-positive individuals occurred in 2022 as individuals initiated ART.""

Rationale: The paper explicitly states the year when the samples were obtained.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper describes the use of Sanger sequencing, which does not require cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""This covered the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids).""

Rationale: The paper explicitly states the HIV genes that were sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""The amplified products were sequenced by Sanger sequencing.""

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""Viral RNA was extracted from 200 µL plasma samples using the QIAamp viral RNA mini kit (Qiagen, Hilton, Germany) according to the operational instructions.""

Rationale: The paper explicitly states the type of samples that were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""3.2% (n=81) of participants had prior ARV drug exposure.""

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""3.2% (n=81) of participants had prior ARV drug exposure.""

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about the drug classes received by individuals before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about the drugs received by individuals before sample sequencing.

Answer: Not reported",83
37976185,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Of 10 356 people with a new HIV diagnosis assigned for partner services in this time period, a total of 4246 (40%) had an available genotype obtained within 30 days of diagnosis"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 4246

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which suggests that it is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2015 and 2022.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2015-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that it is not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions the pol gene and the integrase coding region, which suggests that these genes were sequenced.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""plasma specimens/samples"".

Rationale: The paper explicitly mentions plasma samples, which suggests that these were the type of samples sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly mentions virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""prior ARV exposure"".

Rationale: The paper explicitly mentions previous ARV exposure, which suggests that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"" and ""INSTI"".

Rationale: The paper explicitly mentions NRTI and INSTI, which suggests that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir disoproxil fumarate/tenofivir alafenamide fumarate with emtricitabine"".

Rationale: The paper explicitly mentions the specific drugs received by individuals in the study before sample sequencing.

Answer: Tenofovir disoproxil fumarate, tenofivir alafenamide fumarate, emtricitabine",84
37993493,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on patient samples, which indicates that it reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about making sequences publicly available, which suggests that it did not make sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that it did not report such numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 600 individuals participated in the survey.

Rationale: The paper explicitly mentions the number of individuals who participated in the survey, which suggests that it reports the number of individuals who had samples obtained for HIV sequencing.

Answer: 600

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Tanzania.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that it reports the country of origin for the sequenced samples.

Answer: Tanzania

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between February and May 2023.

Rationale: The paper explicitly mentions the time period when the study was conducted, which suggests that it reports the years when the sequenced samples were obtained.

Answer: 2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning samples prior to sequencing, which suggests that it did not clone samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study analyzed the protease, reverse transcriptase, and integrase genes.

Rationale: The paper explicitly mentions the genes that were analyzed, which suggests that it reports the HIV genes that were sequenced.

Answer: Protease, reverse transcriptase, and integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the study used Sanger sequencing.

Rationale: The paper explicitly mentions the sequencing method used, which suggests that it reports the method used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the study analyzed plasma samples.

Rationale: The paper explicitly mentions the type of samples analyzed, which suggests that it reports the type of samples sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study analyzed samples from individuals with unsuppressed viral loads.

Rationale: The paper explicitly mentions that the study analyzed samples from individuals with unsuppressed viral loads, which suggests that it reports sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that it did not report patients in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study analyzed samples from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that the study analyzed samples from individuals who had previously received ARV drugs, which suggests that it reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study analyzed samples from individuals who had received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper explicitly mentions the drug classes received by individuals in the study, which suggests that it reports the drug classes received by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, and INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study analyzed samples from individuals who had received tenofovir, lamivudine, and dolutegravir.

Rationale: The paper explicitly mentions the drugs received by individuals in the study, which suggests that it reports the drugs received by individuals in the study before sample sequencing.

Answer: Tenofovir, lamivudine, and dolutegravir",87
38005921,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotype--phenotype"" datasets were used, which describe a relationship between a viral genotype and the phenotypic manifestation of resistance to protease, and reverse transcriptase and integrase inhibitors from the Stanford HIV Drug Resistance Database. The datasets contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples.

Rationale: The paper reports that the datasets were obtained from the Stanford HIV Drug Resistance Database, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the experimental level of resistance provided in the dataset was determined using the Phenosense test system. The paper also mentions that the models were built using random forest and support vector machine machine learning methods from the library scikit learn 1.1.1.

Rationale: The paper reports that the experimental level of resistance was determined using the Phenosense test system, which suggests that in vitro drug susceptibility data was reported.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the datasets used for building models for the web-service is provided in Supplementary Materials.

Rationale: The paper reports that the datasets are provided in Supplementary Materials, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the total dataset contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples.

Rationale: The paper reports that the total dataset contained a large number of samples, but it does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the datasets contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples.

Rationale: The paper reports that the datasets contained samples from protease, reverse transcriptase, and integrase inhibitors, which suggests that the HIV genes that were sequenced include protease, reverse transcriptase, and integrase.

Answer: Protease, reverse transcriptase, and integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the models were built using random forest and support vector machine machine learning methods from the library scikit learn 1.1.1.

Rationale: The paper reports that the models were built using machine learning methods, but it does not provide information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the datasets contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples.

Rationale: The paper reports that the datasets contained samples from protease, reverse transcriptase, and integrase inhibitors, but it does not provide information on the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the datasets contained samples from individuals with virological failure on a treatment regimen.

Rationale: The paper reports that the datasets contained samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information on whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the datasets contained samples from individuals with virological failure on a treatment regimen.

Rationale: The paper reports that the datasets contained samples from individuals with virological failure on a treatment regimen, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the datasets contained samples from protease, reverse transcriptase, and integrase inhibitors.

Rationale: The paper reports that the datasets contained samples from protease, reverse transcriptase, and integrase inhibitors, which suggests that the individuals received protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors.

Answer: Protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information on the specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported",99
38020274,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions genotypic resistance testing and HIV sequencing.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data, phenotypic susceptibility, or drug susceptibility assays.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA).

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which suggests that they were not provided.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 311 APHI were included in the study.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 311

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper explicitly mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from 2018-2020.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this period.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the HIV-1 polymerase and reverse transcriptase gene regions were sequenced.

Rationale: The paper explicitly mentions the HIV genes that were sequenced, which suggests that the polymerase and reverse transcriptase gene regions were targeted.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it was not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the type of sample used for sequencing, which suggests that plasma samples were targeted.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequencing was performed on participants with virological failure.

Rationale: The paper explicitly mentions that sequencing was performed on individuals with virological failure, which suggests that such sequences were obtained.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any trial-related information.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants were on ART and had previously received ARV drugs.

Rationale: The paper explicitly mentions that participants had previously received ARV drugs, which suggests that such sequences were reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART and had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly mentions the drug classes that were received by participants before sample sequencing, which suggests that NRTIs and NNRTIs were targeted.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART and had previously received specific ARV drugs such as 3TC, FTC, AZT, TDF, and EFV.

Rationale: The paper explicitly mentions the specific ARV drugs that were received by participants before sample sequencing, which suggests that these drugs were targeted.

Answer: 3TC, FTC, AZT, TDF, EFV",79
38022124,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples"" and ""patients who received BIC/FTC/TAF for at least 12 months were included in this study.""

Rationale: The paper mentions that genetic sequencing was performed on clinical samples, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not report that sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 116 patients"" were included in the study.

Rationale: The paper reports that 116 patients had samples obtained for HIV sequencing.

Answer: 116

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Turkey.

Rationale: The paper reports that the sequenced samples were obtained from Turkey.

Answer: Turkey

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between June 2020 and June 2022.

Rationale: The paper reports that the sequenced samples were obtained between 2020 and 2022.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing methods.

Rationale: The paper does not report whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not report which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not report the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""DNA was extracted from whole blood"".

Rationale: The paper reports that plasma and whole blood samples were sequenced.

Answer: Plasma, whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""patients who received BIC/FTC/TAF for at least 12 months were included in this study"" and ""some patients had virological failure"".

Rationale: The paper reports that some patients had virological failure, but it is not clear if sequences were obtained from these patients.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""some patients had previous treatment experience"".

Rationale: The paper reports that some patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""some patients had previous treatment experience with EVG/c/FTC/TAF or DTG+TDF/FTC"".

Rationale: The paper reports that some patients had previously received INSTI and NRTI drugs.

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""some patients had previous treatment experience with EVG/c/FTC/TAF or DTG+TDF/FTC"".

Rationale: The paper reports that some patients had previously received EVG, FTC, TAF, DTG, TDF, and FTC.

Answer: EVG, FTC, TAF, DTG, TDF, FTC",74
38031075,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genetic sequencing were performed on clinical samples such as plasma"", ""patients or participants were recruited in, enrolled in, or followed at hospital or clinic"", and ""genotypic resistance testing"" was performed.

Rationale: The paper mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not report that sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not report any GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""2,253 patients were recruited"".

Rationale: The paper reports that 2,253 patients had samples obtained for HIV sequencing.

Answer: 2,253

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in ""Sierra Leone"".

Rationale: The paper reports that the sequenced samples were obtained from Sierra Leone.

Answer: Sierra Leone

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between ""August 2022 and January 2023"".

Rationale: The paper reports that the sequenced samples were obtained between 2022 and 2023.

Answer: 2022-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not report that samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not report which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not report the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma"" was used for RNA extraction.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic failure"" was reported in some patients.

Rationale: The paper reports that some patients had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some patients were ""ART-experienced"".

Rationale: The paper reports that some patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that some patients received ""dolutegravir-based therapy"" and ""efavirenz-based therapy"".

Rationale: The paper reports that some patients received INSTI and NNRTI drugs.

Answer: INSTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that some patients received ""dolutegravir"" and ""efavirenz"".

Rationale: The paper reports that some patients received dolutegravir and efavirenz.

Answer: Dolutegravir, Efavirenz",70
38033131,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from patients, and it mentions ""HIV sequencing"" and ""Sanger sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"".

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""492 patient charts"" were included in the analysis.

Rationale: The paper explicitly mentions the number of patient charts included in the analysis, which suggests that 492 individuals had samples obtained for HIV sequencing.

Answer: 492

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in ""East Shewa, Oromia region, Ethiopia"".

Rationale: The paper explicitly mentions the location where the study was conducted, which suggests that the sequenced samples were obtained from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted from ""January 2015 to December 2019"".

Rationale: The paper explicitly mentions the time period during which the study was conducted, which suggests that the sequenced samples were obtained between 2015 and 2019.

Answer: 2015-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that this information is not available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger sequencing"" was used.

Rationale: The paper explicitly mentions the sequencing method used, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""plasma"" samples were used.

Rationale: The paper explicitly mentions the type of sample used, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""virological failure"" was one of the outcomes measured.

Rationale: The paper explicitly mentions that virological failure was one of the outcomes measured, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some patients had ""prior ARV exposure"".

Rationale: The paper explicitly mentions that some patients had prior ARV exposure, which suggests that HIV sequences from individuals who had previously received ARV drugs are reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received ""NRTI"" and ""NNRTI"" drugs.

Rationale: The paper explicitly mentions the drug classes received by some patients, which suggests that NRTI and NNRTI drugs were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some patients received ""AZT"", ""3TC"", and ""NVP"" drugs.

Rationale: The paper explicitly mentions the specific drugs received by some patients, which suggests that AZT, 3TC, and NVP drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, NVP",83
38058846,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper reports that ""genotypic resistance testing"" was performed on samples from patients, and it mentions ""HIV sequencing"" and ""Sanger"" sequencing. The paper also mentions that the patients were ""ART-experienced"" and that the sequencing was done on ""plasma"" samples.

Rationale: The paper mentions that genotypic resistance testing was performed on patient samples, which indicates that HIV sequences were obtained from these samples. Additionally, the paper mentions HIV sequencing and Sanger sequencing, which are methods used to obtain HIV sequences. The paper also mentions that the patients were ART-experienced, which suggests that the sequencing was done to monitor drug resistance.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". It also does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". It also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: Since the paper does not report GenBank accession numbers, we cannot provide an answer to this question.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that there were three cases of DTG resistance in pregnant and breastfeeding women in South Africa.

Rationale: The paper mentions that there were three cases, which suggests that samples were obtained from three individuals.

Answer: 3

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from South Africa.

Rationale: The paper explicitly mentions South Africa as the country where the samples were obtained.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained between 2018 and 2023.

Rationale: The paper provides a timeline of the events, which suggests that the samples were obtained between 2018 and 2023.

Answer: 2018-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that we cannot determine whether cloning was done or not.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the ""pol"" gene.

Rationale: The paper explicitly mentions the ""pol"" gene, which suggests that this gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions Sanger sequencing, which suggests that this method was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were sequenced.

Rationale: The paper explicitly mentions plasma samples, which suggests that these samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the individuals had virological failure on a treatment regimen.

Rationale: The paper explicitly mentions virological failure, which suggests that the sequences were obtained from individuals who had failed treatment.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the individuals had previously received ARV drugs.

Rationale: The paper explicitly mentions previous ARV drug use, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals received NRTIs, NNRTIs, and INSTIs.

Rationale: The paper explicitly mentions these drug classes, which suggests that the individuals received these classes of drugs before sample sequencing.

Answer: NRTIs, NNRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals received DTG, TDF, FTC, and other drugs.

Rationale: The paper explicitly mentions these drugs, which suggests that the individuals received these drugs before sample sequencing.

Answer: DTG, TDF, FTC, and other drugs",82
38072961,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from a patient with HIV infection. The paper also mentions that CSF HIV RNA was detectable and that HIV drug resistance tests were performed.

Rationale: The paper reports that genetic sequencing was performed on a clinical sample from a patient with HIV infection, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related assays.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to a public database or made available.

Rationale: The paper does not provide any information about the availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper is a case report, which means that only one individual had a sample obtained for HIV sequencing.

Rationale: The paper is a case report, which meets the criteria for a ""1"" answer.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the patient is a Chinese Manchu male.

Rationale: The paper mentions the patient's ethnicity and nationality, which meets the criteria for a ""China"" answer.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient was diagnosed with HIV infection five years ago and that the samples were obtained in 2022.

Rationale: The paper provides information about the year of diagnosis and the year of sample collection, which meets the criteria for a ""2022"" answer.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related techniques.

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that HIV drug resistance tests were performed, which likely involved sequencing of the pol gene.

Rationale: The paper mentions HIV drug resistance tests, which likely involved sequencing of the pol gene, which meets the criteria for a ""Pol"" answer.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing, which meets the criteria for a ""Sanger sequencing"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that CSF and plasma samples were obtained from the patient.

Rationale: The paper mentions CSF and plasma samples, which meets the criteria for a ""CSF and plasma"" answer.

Answer: CSF and plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient experienced virological failure on a treatment regimen.

Rationale: The paper mentions virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""No"" answer.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient had previously received ARV drugs.

Rationale: The paper mentions previous ARV drug use, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had previously received NRTIs, PIs, and NNRTIs.

Rationale: The paper mentions previous use of NRTIs, PIs, and NNRTIs, which meets the criteria for a ""NRTIs, PIs, NNRTIs"" answer.

Answer: NRTIs, PIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had previously received tenofovir, lamivudine, lopinavir/ritonavir, and efavirenz.

Rationale: The paper mentions previous use of specific drugs, which meets the criteria for a ""tenofovir, lamivudine, lopinavir/ritonavir, efavirenz"" answer.

Answer: tenofovir, lamivudine, lopinavir/ritonavir, efavirenz",81
38090027,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1040 patients were included in the analysis.

Rationale: The paper explicitly mentions the number of patients included in the analysis, which indicates that 1040 individuals had samples obtained for HIV sequencing.

Answer: 1040

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples, which suggests that it is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from June 2019 to June 2021.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which indicates that the sequenced samples were obtained between 2019 and 2021.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""HIV sequencing"", but it does not specify which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that it is not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""PBMCs"", but it does not specify the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced, which suggests that it is not reported.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that virological failure occurred in 44 patients.

Rationale: The paper explicitly mentions that virological failure occurred in some patients, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patients were treatment-experienced.

Rationale: The paper explicitly mentions that the patients were treatment-experienced, which indicates that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" classes.

Rationale: The paper explicitly mentions the drug classes received by the individuals in the study, which indicates that they received NRTI, NNRTI, PI, and INSTI classes.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""bictegravir"", ""emtricitabine"", ""tenofovir alafenamide"", and ""elvitegravir"".

Rationale: The paper explicitly mentions the specific drugs received by the individuals in the study, which indicates that they received bictegravir, emtricitabine, tenofovir alafenamide, and elvitegravir.

Answer: Bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir",88
38140553,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions the use of plasma, PBMC, and whole blood samples.

Rationale: The paper explicitly mentions the use of patient samples for genetic sequencing, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related experiments.

Rationale: The paper focuses on sequencing, phylogenetics, and epidemiology, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.

Rationale: The paper explicitly mentions the deposition of sequences in a public database, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers, but mentions that the sequences were deposited in the Los Alamos database.

Rationale: The paper does not provide explicit accession numbers, but mentions the deposition of sequences in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 3178 HIV-infected patients had samples obtained for sequencing.

Rationale: The paper explicitly mentions the number of patients who had samples obtained for sequencing.

Answer: 3178

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from Russia.

Rationale: The paper explicitly mentions the country of origin for the samples.

Answer: Russia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between 2011 and 2020.

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2011-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on cloning, and the sequencing methods mentioned do not imply cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol gene was sequenced, which includes the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions the pol gene as the target for sequencing.

Answer: Pol (PR, RT)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing and ABI instruments.

Rationale: The paper explicitly mentions the use of Sanger sequencing and ABI instruments, which meets the criteria for a ""Sanger sequencing"" answer.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions the use of plasma, PBMC, and whole blood samples.

Rationale: The paper explicitly mentions the use of multiple sample types.

Answer: Plasma, PBMC, Whole Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some patients were experiencing virological failure.

Rationale: The paper explicitly mentions virological failure, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on a clinical trial, and the study design does not imply a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some patients were ART-experienced.

Rationale: The paper explicitly mentions ART-experienced patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information on drug classes.

Rationale: The paper does not provide explicit information on drug classes, but mentions ART-experienced patients.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information on drugs.

Rationale: The paper does not provide explicit information on specific drugs.

Answer: Not reported",72
38140649,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"". The paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance (TDR), or transmission clusters without reporting in vitro susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly states that sequences were submitted to public databases, which indicates that they are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper provides the accession numbers for the sequenced HIV isolates, which can be used to retrieve the sequences from GenBank.

Answer: OR605755-OR606279 and OR613869-OR613875

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 270 persons met the inclusion criteria.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 270

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia.

Rationale: The paper explicitly states the country where the study was conducted, which suggests that the sequenced samples were obtained from Croatia.

Answer: Croatia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted from January 2019 to December 2022.

Rationale: The paper explicitly states the time period during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any cloning-related techniques.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 pol gene was sequenced, including the protease and reverse transcriptase regions.

Rationale: The paper explicitly states the HIV genes that were sequenced, which suggests that the pol gene, including the protease and reverse transcriptase regions, was sequenced.

Answer: Pol (protease and reverse transcriptase regions)

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing and next-generation sequencing (NGS) using the Illumina platform.

Rationale: The paper explicitly states the sequencing methods used, which suggests that both Sanger sequencing and NGS were used.

Answer: Sanger sequencing and NGS (Illumina platform)

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma.

Rationale: The paper explicitly states the type of sample that was sequenced, which suggests that plasma samples were used.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included treatment-naive individuals.

Rationale: The paper explicitly states that the study included treatment-naive individuals, which suggests that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included treatment-naive individuals.

Rationale: The paper explicitly states that the study included treatment-naive individuals, which suggests that no HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included treatment-naive individuals.

Rationale: The paper explicitly states that the study included treatment-naive individuals, which suggests that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included treatment-naive individuals.

Rationale: The paper explicitly states that the study included treatment-naive individuals, which suggests that no drugs were received by individuals in the study before sample sequencing.

Answer: None",94
38140667,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing.

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported in the paper.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay, and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not report that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), and it does not provide accession numbers for GenBank or any of the above databases.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers, which makes it impossible to answer this question.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 3219 individuals received DTG-based regimens, but it does not explicitly state how many individuals had samples obtained for HIV sequencing.

Rationale: The paper does not provide a clear answer to this question, which makes it impossible to determine the exact number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected in France, Tanzania, Malawi, Mozambique, and other countries, but it does not provide a comprehensive list of countries.

Rationale: The paper provides some information about the countries where samples were collected, but it does not provide a complete list.

Answer: France, Tanzania, Malawi, Mozambique, and other countries

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected between 2012 and 2022, but it does not provide a specific year range.

Rationale: The paper provides some information about the time period during which samples were collected, but it does not provide a specific year range.

Answer: 2012-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning, TA cloning, or Topo TA cloning, and it does not describe clonal analyses or clonal sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the integrase coding region of pol was sequenced, and it mentions INSTI resistance and integrase sequencing.

Rationale: The paper explicitly mentions that the integrase coding region of pol was sequenced, which suggests that the IN gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing, but it does not provide any information about the sequencing method used.

Rationale: The paper mentions Sanger sequencing, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were sequenced, and it mentions viral RNA extraction from plasma.

Rationale: The paper explicitly mentions that plasma samples were sequenced, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, and it mentions treatment-emergent resistance.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that such sequences were obtained.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial, and it does not provide any information about trial participation.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs, and it mentions treatment-experienced individuals.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs, which suggests that such sequences were reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that individuals received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing.

Rationale: The paper explicitly mentions that individuals received these drug classes before sample sequencing, which suggests that these classes were received.

Answer: NRTIs, NNRTIs, PIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that individuals received DTG, 3TC, ABC, TDF, FTC, EFV, RPV, ATV, DRV, and other drugs before sample sequencing.

Rationale: The paper explicitly mentions that individuals received these drugs before sample sequencing, which suggests that these drugs were received.

Answer: DTG, 3TC, ABC, TDF, FTC, EFV, RPV, ATV, DRV, and other drugs",95
38142692,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it does not report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers, which suggests that they are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1214 participants were included in the study.

Rationale: The paper explicitly mentions the number of participants, which indicates that 1214 individuals had samples obtained for HIV sequencing.

Answer: 1214

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in South Africa.

Rationale: The paper explicitly mentions the country where the study was conducted, which indicates that the sequenced samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between December 1, 2019, and November 30, 2020.

Rationale: The paper explicitly mentions the time period during which the study was conducted, which indicates that the sequenced samples were obtained between 2019 and 2020.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""pol genotyping/sequencing"" was performed.

Rationale: The paper explicitly mentions that ""pol genotyping/sequencing"" was performed, which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it is not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""plasma HIV-1 RNA"" was used for sequencing.

Rationale: The paper explicitly mentions that ""plasma HIV-1 RNA"" was used for sequencing, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that participants had virological failure on first-line NNRTI-based regimens.

Rationale: The paper explicitly mentions that participants had virological failure on a treatment regimen, which indicates that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants had previously received ARV drugs.

Rationale: The paper explicitly mentions that participants had previously received ARV drugs, which indicates that HIV sequences from individuals who had previously received ARV drugs are reported.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants received NNRTI-based regimens.

Rationale: The paper explicitly mentions that participants received NNRTI-based regimens, which indicates that NNRTI was one of the drug classes received by individuals in the study.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants received efavirenz (EFV) and nevirapine (NVP).

Rationale: The paper explicitly mentions that participants received EFV and NVP, which indicates that these drugs were received by individuals in the study.

Answer: EFV, NVP",84
38152686,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotyping was requested, with detection of the *H51Y* and *E157Q* mutations in the integrase."" and ""The baseline viral load (VL) was 437,927 cp/mL (Log = 5.64)."".

Rationale: The paper mentions genotyping and detection of specific mutations in the integrase gene, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical case of a patient who developed HIV treatment failure during dolutegravir therapy, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions a single patient case.

Rationale: The paper is a case report, and it only mentions one patient.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not provide any information about the country of origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years of sample collection.

Rationale: The paper does not provide any information about the years of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the integrase gene.

Rationale: The paper specifically mentions the detection of mutations in the integrase gene.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions plasma samples.

Rationale: The paper mentions that the baseline viral load was measured from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient experienced virological failure during dolutegravir therapy.

Rationale: The paper specifically mentions that the patient experienced virological failure, which suggests that sequences were obtained from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was treated with dolutegravir.

Rationale: The paper specifically mentions that the patient was treated with dolutegravir, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions dolutegravir, which is an INSTI.

Rationale: The paper specifically mentions dolutegravir, which is an INSTI.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions dolutegravir.

Rationale: The paper specifically mentions dolutegravir.

Answer: Dolutegravir",65
38314093,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-infected blood samples were sent to the Guangdong AIDS Prevention Center for genotypic resistance testing."" and ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions that HIV-infected blood samples were sent for genotypic resistance testing, which involves sequencing the HIV genome. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""Sequences were submitted to the Stanford University HIV resistance database (http://hivdb.stanford.EDU) for subtype identification, resistance loci, and drug sensitivity analysis.""

Rationale: The paper mentions that the sequences were submitted to a database for drug sensitivity analysis, but it does not provide in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about the GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""serum samples from 37 untreated patients [29 men (78%); 8 women (22%)] obtained from Meizhou People's Hospital were included.""

Rationale: The paper mentions that 37 untreated patients had their serum samples obtained for HIV sequencing.

Answer: 37

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from Meizhou People's Hospital in China.

Rationale: The paper mentions that the samples were obtained from a hospital in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between May 2008 and December 2019.

Rationale: The paper mentions the time period during which the samples were collected.

Answer: 2008-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions that the PR-RT sequence of HIV-1 was amplified and sequenced.

Answer: PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""high-throughput sequencing"" was used.

Rationale: The paper mentions that high-throughput sequencing was used, but it does not provide more specific information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""HIV-infected blood samples"" were sent for genotypic resistance testing.

Rationale: The paper mentions that blood samples were used for sequencing.

Answer: Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""most resistant mutations were related to NRTIs and NNRTIs; only one case carried a mutation resistant to PIs.""

Rationale: The paper mentions that some individuals had resistant mutations, which suggests that they may have had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""most resistant mutations were related to NRTIs and NNRTIs.""

Rationale: The paper mentions that some individuals had resistant mutations, which suggests that they may have previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""most resistant mutations were related to NRTIs and NNRTIs.""

Rationale: The paper mentions that some individuals had resistant mutations to NRTIs and NNRTIs, which suggests that they may have received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs received by individuals before sample sequencing.

Answer: Not reported",80
38427738,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from patients, and it mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"", and it reports values such as IC50 and fold-change in susceptibility.

Rationale: The paper explicitly states that it reports phenotypic susceptibility data, which indicates that it reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for GenBank.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for GenBank, but they are not explicitly listed in the provided text.

Rationale: The paper mentions that accession numbers are provided, but they are not explicitly listed in the provided text.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not Reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"", which suggests that the pol gene was sequenced.

Rationale: The paper explicitly states that the pol gene was sequenced, which includes the integrase coding region.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the method used for sequencing.

Rationale: The paper does not provide information on the method used for sequencing.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"", which suggests that both plasma and PBMC samples were sequenced.

Rationale: The paper explicitly states that both plasma and PBMC samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"", which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"", which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", and ""INSTI"", which suggests that individuals received these drug classes before sample sequencing.

Rationale: The paper explicitly states that individuals received these drug classes before sample sequencing.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", and ""lenacapavir"".

Rationale: The paper explicitly states that individuals received these specific drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",96
38864613,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""GenBank accession numbers"" for sequences generated in this study. The paper also states that genetic sequencing was performed on clinical samples from ""patients"" and ""participants"".

Rationale: The paper reports HIV sequences from patient samples, as indicated by the mention of genotypic resistance testing, HIV sequencing, and GenBank accession numbers. The paper also explicitly states that genetic sequencing was performed on clinical samples from patients and participants.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"". The paper also reports values such as IC50 and fold-change in susceptibility.

Rationale: The paper reports in vitro drug susceptibility data, as indicated by the mention of phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay. The paper also reports specific values such as IC50 and fold-change in susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides accession numbers for GenBank.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, indicating that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for GenBank, specifically PP827803 -- PP828572.

Rationale: The paper explicitly provides accession numbers for GenBank, which can be used to access the sequenced HIV isolates.

Answer: PP827803 -- PP828572

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper reports that the pol gene, including the integrase coding region, was sequenced.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" samples.

Rationale: The paper reports that both plasma and PBMC samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"" in the context of sequencing.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" individuals.

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", and ""INSTI"" drug classes.

Rationale: The paper reports that individuals in the study received NRTI, PI, and INSTI drug classes before sample sequencing.

Answer: NRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", and ""lenacapavir"".

Rationale: The paper reports that individuals in the study received specific drugs from various drug classes before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",92
